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ABSTRACT 
IgE is the class of immunoglobulins responsible for the protection against intestinal parasites and 
exerts a key role in the pathophysiology of allergic reactions. In addition, it has been 
demonstrated its involvement in the immune response against tumors in various animal models. 
According to our model, the function of IgE in the anti-tumor response is mediated by the binding 
of IgE with its high affinity receptor FcεRI expressed, in mice, on the surface of mast cells and 
basophils. Activation of FcεRI receptor leads to cell degranulation with release of preformed and 
newly synthesized mediators able to recruit effector cells that induce the establishment of a 
powerful inflammation at the tumor site. This inflammation, leading to cell death, could determine 
the processing of tumor antigens and the resulting immune response against tumor. 
Based on promising data obtained previously in our laboratories, regarding the adjuvant effect of 
exogenous IgE in the anti-tumor vaccination and on the many controversial epidemiological 
studies about a possible link between allergies and cancer protection, we decided to investigate 
the possible role of endogenous IgE in the immunosurveillance of tumor. The use of two 
transgenic mouse models, one knock-out for the production of IgE (IgE-KO mice) and the other 
high IgE producer (KN1 mice), allowed us to investigate the possible involvement of host 
endogenous IgE in the immunity against cancer. Either in the absence or with a normal amount of 
IgE, tumor growth, preceded by vaccination with irradiated TS/A tumor cells (mammary 
adenocarcinoma), is not hindered and is comparable to not immunized mice. Differently, in high 
IgE producer mice, a single immunization was sufficient to obtain a complete anti-tumor 
protection. Moreover, challenging mice with a different tumor cell line, N2C tumor cells (less 
aggressive than TS/A tumor cells), the anti-tumor protection is observed even without 
immunization in 100% of KN1 mice compared to IgE-KO and wild type control mice. 
To demonstrate that the protection observed in KN1 mice is due to the interaction of IgE with its 
high affinity FcRI receptor, we decided to delete the FcRI alpha gene in KN1 mice to remove 
their receptor. For this purpose we crossed KN1 mice with FcRI-KO mice, in order to obtain a 
double-mutant mouse model (DM), characterized by elevated levels of IgE but lacking in the 
expression of the high affinity receptor for IgE. The inoculation of N2C tumor cells in DM mice 
showed that the previously anti-tumor protection, observed in KN1 mice, has been widely lost and 
this is the fundamental point of this study because demonstrates that IgE-FcRI axis is the basis of 
the role of IgE in anti-tumor immune response. 
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We also demonstrated, through an in vitro test of mediators release, the existence of tumor-
specific IgE in the serum of KN1 and DM mice that were challenged in vivo with N2C tumor cells; 
moreover, the depletion of IgE from sera of KN1 and DM mice validate the specific contribution 
played by IgE in the mediators release. 
Another point of this study was to understand how IgE acts in the observed anti-tumor effect. KN1 
mice depleted of CD8+ T cells prior to tumor cells inoculation lost the anti-tumor protection. This 
result allowed us to point out that the anti-tumor immunosurveillance, driven by IgE, is largely 
mediated by an immune response dependent on CD8+ T cells. Next, we decided to isolate tumor-
specific IgE through hybridoma technology, starting from spleen or bone marrow of KN1 mice that 
previously rejected the tumor in vivo. We tried to isolate tumor-specific IgE to employ them either 
in preventive vaccination or in therapeutic treatment protocols, in mice with already developed 
tumors, but unfortunately we were able to isolate a very low number of IgE secreting hybridoma 
that didn't show any specificity against the tumor cells.  
Without any tumor-specific IgE, we planned a different approach for treating solid tumors, 
through intratumoral injection of rMVA-tmIgE (Modified Vaccinia Virus Ankara expressing a 
truncated form of the human membrane IgE), previously developed in our laboratories. This 
rMVA-tmIgE allowed to obtain tumor-infected cells expressing the Cε3Cε4 fragment of human IgE 
on their cell surface. Since MVA does not replicate among the infected cells without any effect on 
the surrounding host cells, the expression of Cε3Cε4 is restricted only in the tumor.  
Several studies have also demonstrated the efficacy of the intratumoral treatment (i.t.) with 
vectors based on MVA, showing a consequent reduction of the tumor mass volume and an 
increased survival of treated mice. For this reason, in the last part of this project, we have 
evaluated the ability of rMVA-tmIgE to express, in vivo, the human membrane IgE on the tumor 
cells surface after intratumoral treatment of wild type mice with the vaccine. N2C tumor mass, 
treated i.t. with 107 plaque-forming unit (pfu) of rMVA-tmIgE, showed 24 and 48 hours after 
treatment a good infection efficiency. Moreover, the ability of rMVA-tmIgE to express human IgE 
in vivo was evident just one day after the intratumoral treatment, even if the signal of the Cε3Cε4 
expression was much lower compared to the signal of MVA infection. This preliminary data is the 
first evidence that rMVA-tmIgE can be used to treat solid tumors in the mouse model "humanized" 
for the high affinity receptor of IgE (FcεRIα-/-/hFcεRIα+). Indeed, our previous studies, based on 
preventive vaccination protocols, have shown the efficacy of rMVA-tmIgE in countering tumor 
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growth in the “humanized” mice model. In the near future we will determine the effect of i.t. 
rMVA-tmIgE in humanized mice carrying a solid tumor 
We expect to achieve an inflammatory reaction against the tumor induced by the binding of IgE, 
expressed on tumor cells, with FcεRI receptor expressed on the surface of immune cells. We think 
that this initial IgE-dependent response would lead to long-term protection through the activation 
of an immune cascade where CD8+ T cells are surely involved. 
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INTRODUCTION 
Immune System 
The immune system defends body against infections elicited by foreign invaders such as virus or 
bacteria. Immune system consists of different cells, tissues and organs that collaborate together to 
recognize and eliminate agents potentially capable of disrupting the body's integrity. The key role 
of immune system is to distinguish the body's cells (self) from the foreign cells (non-self). In fact, it 
recognizes "self-marker molecules" expressed on self-cells, but when it encounters cells or 
organisms displaying "foreign-marker molecules”, a response to eliminate them is rapidly 
triggered. Every molecule that activates this immune response is called “Antigen” (Ag), and it can 
be a part of a microbe, virus, cell or tissue from another person (with the exception of an identical 
twin) which is recognized as non-self. 
The immune system employs two ways to protect body against infections: the innate immune 
system and the adaptive immune system. 
The innate immune system is the first to intervene and involves different tools to respond to an 
infection. The main components of the innate immune system are represented by physical 
epithelial barriers, leukocytes, dendritic cells, and natural killer (NK) cells (Janeway CA Jr and 
Medzhitov R 2002). The epithelium that covers the respiratory tract and the gastrointestinal tract 
are our primary defense against microbial infection; in these tracts, mucous secretion by epithelial 
cells creates a physical obstacle to the passage of microbes, and antimicrobial chemical secretions 
by epithelial cells inhibit bacterial growth. Moreover, in the gastrointestinal tract many ingested 
microbes are killed or neutralized by stomach acid and digestive enzymes. 
Cells included in the innate immune system are represented by leukocytes (a class of white blood 
cells) composed by Natural killer (NK) cells, mast cells (MC), eosinophils, and basophils; also 
phagocytic cells, such as macrophages, neutrophils and dendritic cells are included in the cell 
repertoire of innate immune system. All these cells derived from CD34+ pluripotent hematopoietic 
stem cells, present in the bone marrow (Bruce A et al. 2002). Leukocytes act identifying cellular 
debris or foreign particles, and eliminating pathogens that could cause an infection (Beutler B 
2004). For example, NK cells kill virus-infected cells and cancer cells in nonspecifically way; they 
act by releasing proteins called “perforin” that produce pores in the cell membrane of target cells; 
pores induce apoptosis of target cells by favoring the entrance of serine proteases (also known as 
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granzymes) that cause cell death and thereby prevent the spread of viruses (Brandstadter JD and 
Yang Y 2011). 
Otherwise, phagocytic cells are responsible for the production of chemokines and cytokines which 
trigger inflammation and other responses such as the induction of apoptosis and phagocytosis of 
infected cells (Beutler B 2004; Arango DG and Descoteaux A 2014). Moreover, macrophages and 
dendritic cells are also called APC (Antigen-presenting Cells), since they are able to present the 
antigen on their surface, through the MHC (Major Histocompatibility Complex) class II, and 
activate the adaptive immune system through the stimulation of T CD4+ lymphocytes (also known 
as T helper) (Banchereau J and Steinman RM 1998).  
These mechanisms are always present and may enter in action at a remarkable speed. However, 
the innate immune system does not always have the power to eliminate the infection and it is not 
able to confer a long-lasting immunity against pathogens. 
 
 
Figure 1. Main components of the innate immune system that are implicate in the first hours of immune response. 
 
 
On the other hand, the adaptive immune system focuses specifically on defeating pathogens and 
evokes a long-lasting protection against that particular germ. In contrast to the innate immune 
response, which always possess the same repertoire of molecules to recognize the pathogens, the 
adaptive immune response uses millions of various immunoglobulins (Ig) and T cell receptor (TCR), 
each of which recognizes a different molecular structure (Cooper MD and Alder MN 2006). The 
cells that constitute adaptive immune system are formed in the bone marrow, where they often 
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ripen and subsequently migrate, through the blood and lymphatic system, towards the periphery 
to monitor tissues. These cells are called B lymphocytes (or B cells) and T lymphocytes (or T cells) 
and derived from hematopoietic stem cells of bone marrow (as leukocytes of innate immune 
system). Lymphocytes are unique cells which have specific receptors for the antigen and, 
therefore, represent the heart of adaptive immunity; even though both originate in the bone 
marrow, B and T lymphocytes differ in function, compartment where differentiation take place, 
and in the expression of different antigen receptors.  
B lymphocytes grow in the bone marrow before encountering the antigen; subsequently, they 
move to the peripheral lymphoid tissues where interact with foreign antigens. Antigen binds and 
activates the receptor, represented by IgM and IgD, expressed on the surface of naïve B 
lymphocytes. This activation can be dependent or independent from T lymphocytes and leads to 
proliferation of the clone of B lymphocytes specific for the antigen, leads to their differentiation 
that consists in the generation of plasma cells that actively secrete antibodies and, finally leads to 
the production of memory B lymphocytes. Activated B cells may start to produce antibodies other 
than IgM and IgD, a defined class exchange process of heavy chains. The activation of B cells and 
the resulting antibody responses to antigens require the collaboration of T helper CD4 + cells able 
to recognize the same antigens. The definition of “T helper” cells derived from the fact that these 
cells "help" B cells to produce antibodies, stimulating B cells through different mechanisms. B 
lymphocytes, at this point, differentiate into cells which produce antibodies and in long survival 
memory cells. In fact, some plasma cells migrate from secondary lymphoid organs to the bone 
marrow, where they may remain for several years producing low levels of antibodies that provide 
long-lasting protection against specific antigen. 
As we have mentioned, also the T cells are a part of the adaptive immune system. T lymphocytes 
arbitrate cell mediated immunity, indeed, their antigen-receptors recognize only peptides of 
antigens conjugated to molecules specialized to present the antigen, called MHC expressed on 
APC. T cells that express CD4 molecule are called T helper cells because they help both B 
lymphocytes to produce antibodies and phagocytes to destroy microbes embedded; instead, T 
cells that express CD8 molecule are called cytotoxic T cells (CTL) because they kill cells which 
possess intracellular microbes. 
If the response by adaptive immunity is successful, it establishes a long-lasting protection against 
the pathogen that caused the response. A failure may be caused by immune deficiency or by the 
ability of pathogen to deceive the immune response (Parham P 2001). 
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Figure 2. Main components of the adaptive immune system that enter in action against pathogens that are able to 
evade or overcome innate immune defenses. 
 
 
Immunoglobulins 
In 1890, von Behring and Kitasato temporarily immunized an animal to diphtheria by injecting 
blood serum of another animal infected with this germ. They demonstrated that this serum had 
not only preventive but also curative properties since when injected at the first symptoms of 
diphtheria, it induced the healing of the affected animal. Through this study, Behring and Kitasato 
discovered an agent present in the blood which was capable to neutralize diphtheria toxin: this 
agent was the immunoglobulin. After 100 years, the study of the structure and function of 
immunoglobulins, highlights the complex nature and importance of these proteins. 
Immunoglobulins are glycoproteins with a quaternary structure, formed by two heavy chains (H) 
and two light chains (L); each chain consists of variable (V) and constant regions (C) with 
immunoglobulin domains, covalently linked by disulfide bonds, electrostatic interactions and Van 
Der Waals forces. Each immunoglobulin domain contains about 100 amino acids arranged in a β 
structure, formed by 3 and 4 β sheets (William AF and Barclay AN 1988). The light and heavy 
chains variable regions constitute two identical binding sites for the antigen which, together with 
the adjacent constant domains, form the antibody Fab region. The remaining immunoglobulin 
domains form, instead, the Fc region of the antibody that contains the binding domains for the FcR 
receptor.  
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Figure 3. Immunoglobulin structure. 
 
 
Within the variable domains, there are three regions characterized by a much higher variability 
than the rest of the domain, called hyper variable regions or complementarity-determining regions 
(CDR1-3). These regions have different sequences in different immunoglobulins, determining the 
specificity of the binding during the antibody-antigen recognition. The light chains are divided into 
two classes called λ, and κ; the heavy chains are divided into five different classes called μ, δ, γ, α 
and ε enabling the division of immunoglobulin in as many isotypes called IgM, IgD, IgG, IgA, and 
IgE, characterized by different effector properties (Bengten E et al. 2000). There is also another 
subclassification for IgG and IgA, respectively γ1, γ2, γ3, γ4 and α1, α2 (Woof JM and Burton DR 
2004). The different classes of heavy chains are capable to combine with both light chains, but the 
number of constant domains is that diversifies, at the structural level, the different isotypes of 
immunoglobulins. IgD, IgG and IgA have, in fact, three constant domains CH, whereas IgM and IgE 
possess four constant domains. There is also, between the first and the second CH domain, a hinge 
region rich in proline, serine and threonine, that gives to the region highly flexible properties; this 
flexibility is essential to modulate the distance between the two binding sites for the antigen 
present in the antibody. 
 
The Generation of Antibody Diversity 
Immunoglobulin form a part of B lymphocytes receptor (BCR); immunoglobulins, as population, 
can bind an infinite number of ligands (antigens) totally different one from each other, and this 
ability is given by a complex series of mechanisms that alter DNA of each B cell. 
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During our life, the immune system encounters thousands of different antigens from bacteria, 
viruses and other microorganisms and this raises the question on how antibody diversity is 
generated during development. Nature has invented an ingenious solution to overcome this 
problem: the combinatorial design of the variable regions of antibodies.  
During maturation of the immune system, antibodies are generated by random fusion of the 
variable segments of the light and heavy chains through a process called V(D)J-recombination, that 
is catalyzed by the DNA recombinases RAG-1 and RAG-2.V(D)J recombination takes place in the 
bone marrow for B cells and in the thymus for T cells, and in a almost random manner rearranges 
variable (V), joining (J), and in some cases, diversify (D) gene segments (Hoehn KB et al. 2016). 
In the germline, the genetic locus of the light chain consists of up to 40 V-segments and 5 J-
segments; the heavy chain contains 50 V-segments, 27 D-segments and 6 J-segments.  
For the light chain, one V-segment gets fused to one of the J-segments by recombination. The 
production of the variable heavy chain occurs in two steps, in the first step one of the J-segments 
is fused to the D-segment, and, later the combined DJ-sequence is added to one of the V-
segments. The recombined antibody gene is transcribed together with the constant region of the 
antibody that is added as exon by splicing, and finally, heavy and light chains are assembled into a 
functional antibody. Stability of the secreted antibodies is reached by covalent disulfide bonds 
between heavy and light chains. Since each antibody is generated by combinatorial fusion of one 
of 40 V-segments, 5 J-segments for the light chain and one of 50 V-, 27 D- and 6 J-segments for the 
heavy chain, the number of possible combinations amounts to 1.6 x 106. Furthermore, during the 
recombination process additional mutations are introduced. This increases the number of possible 
rearrangements to more than 1010 (Hoehn KB et al. 2016). 
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Figure 4. VDJ rearrangement to assemble a functional and specific immunoglobulin. 
 
 
These events lead to the expression of a single type of H and L chain in each B cell; as a 
consequence of these events, in a single B cell and in its progeny is expressed only one type of 
immunoglobulin with a single antigen specificity. In a recent study it was calculated that the 
number of possible BCR sequences is enormous, at least 1018 (Elhanati Y et al. 2015), much higher 
than the number of B cells present in the body. 
Sometimes, the V(D)J recombination can generate inactive recombinant sequences that cause B 
cell apoptosis; the remaining cells, naïve B lymphocytes, are subjected to a first round of selection 
for the lack of self-reactivity prior to being released from the bone marrow (Janeway CA Jr et al. 
2001). The biological development of B cells is therefore characterized by a first phase with an 
antigen-independent clonal expansion of the progenitors followed by a second phase 
distinguished by maturation, induced by the antigenic stimulus leading finally to the formation of 
mature plasma cells and memory B cells. 
Initially, immunoglobulins expressed on the membrane (membrane immunoglobulin, mIg) are 
produced and these bind their specific antigens, but, this interaction alone is not able to activate 
intracellular signals that should follow the link with Ag; in fact, the cytoplasmic portions of the mIg 
molecule are very short and are not able to interact with intracellular proteins. The mIg-Ag 
interaction, occurring on the membrane, are communicated within the cell by two trans-
membrane proteins, called Igα and Igβ that are associated with membrane Ig. These auxillary 
proteins have an extracellular portion and a cytoplasmic tail containing the ITAM motif 
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(Immunoreceptor Tyrosine-based Activation Motif) involved in intracellular signalling; therefore, 
the functional B cell receptor (BCR), is in fact a complex formed by the mIg, Igα and by Igβ proteins 
(Abbas AK et al. 2002). 
Following alternative splicing of mRNA, the C-terminal domainof Ig is changed and this leads to 
secretion of Ig (soluble immunoglobulin, sIg) characterized by the same specificity of the mIg 
(Gould HJ et al. 2003). This event also involves the modification of functional Ig because the Fc 
portion of the sIg is able to interact with receptors expressed on effector cells leading to activation 
of the mechanisms responsible for antigen elimination. 
 
IgE: structure and functions 
IgE consist of 2 heavy (ε ) and 2 light ( or )chains; they are characterized by the ε type heavy 
chain that contains one variable region VH and 4 domains of the constant region, Cε1-4. The extra 
domain (Cε2) present in IgE appears to be critical regarding the peculiar physical properties and 
specific functions of this antibody class, in fact, the Cε2-4 Fc domains confer its isotype-specific 
functions, including binding to its receptors FcεRI and FcεRII (also known as CD23).  
 
Figure 5. Structure of IgE. 
 
 
IgE possess cool features, as they are able to induce a rapid and strong pathologic response and to 
act as a highly sensitive amplifier which causes immunological reactions after the recognition of 
small amounts of antigen even with a small number of IgE. Many aspects of IgE immunobiology 
are interesting, for example its specific cellular receptors, the effector cells that mediate its 
functions, and its immunomodulatory properties (Oettgen HC 2016). 
IgE is an evolutionary conserved member of the immunoglobulin family. Normally, in the serum of 
healthy individuals, all type of Ig are presents in concentration of micro- to milligrams per ml; 
conversely, the titre of IgE is very low compared to others Ig, with a range of nano- to micrograms 
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per ml (Gould HJ et al. 2003) and this concentration reflects the number of circulating B cells 
involved in IgE synthesis. IgE levels are influenced by age, immune status, environmental factors 
and by the presence of diseases.  
Compared to Immunoglobulin G (IgG), which has a half-life of approximately 3 weeks, the half-life 
of IgE is very short. In plasma, the half-life of IgE is less than one day, but, when IgE binds its 
receptor it can remain fixed on mast cell which expressed the receptors for IgE; for this reason IgE 
can remain in tissues for weeks or months, and this long half-life in tissues has considerable clinical 
implication. An example may be given by the passage of sensitivity to an antigen (for example 
towards peanuts) from an organ donor to its recipient mediated by mast cell in which IgE linked its 
receptor. 
IgE are physiologically involved in the immune response against intestinal parasites and 
physiopathologically in allergic responses. Although parasites, such as helminths, activate different 
innate immune mechanisms, these organisms are often able to survive and replicate inside their 
host; as a first line of defense, neutrophils and macrophages attack the worms secreting 
microbicides that allow to kill microbes that are too big to be swallowed from phagocytes. 
Following exposure to an allergen, IgE are capable to trigger an allergic immune response even 
after a few minutes of exposure (type I hypersensitivity) and during this event, IgE activate mast 
cells and basophils, causing degranulation of these cells and release of preformed mediators such 
as histamine, heparin, proteases, and chemokines from cytoplasmic granules (Karagiannis SN et al. 
2012; Leoh LS et al. 2015)and provoking an acute local inflammation (Gould HJ et al. 2003; Gould 
HJ and Sutton BJ 2008). A new exposure to the same allergen leads to a more rapid activation of 
mast cells and basophils, resulting in the recruitment of inflammatory cells such as neutrophils, 
eosinophils, monocytes/macrophages, and T cells (Ying S et al. 1999). 
 
IgE receptors 
The biological functions of IgE antibodies are mediated by their interaction with specific antigens 
and different receptors. There are two IgE receptors, a high-affinity FcεRI receptor and a low 
affinity FcεRII receptor; both of these receptors are proteins expressed on the effector cells 
membrane and are able to specifically bind to the constant region Fc of IgE. As IgE, also other 
antibody isotypes bind their specific receptors present on different cells of immune system, and 
this binding leads to different effector functions including phagocytosis, antibody-dependent 
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cytotoxicity (ADCC), and modulation of cellular secretion of preformed mediators (Metzger H 
2002).  
 
The High-Affinity IgE Receptor (FcRI) 
The high-affinity IgE receptor FcεRI is a multimeric protein expressed in two isoforms, a tetrameric 
2 and a trimeric 2 receptor. In humans, the FcεRI receptor is expressed in large amounts 
(about 2x105 molecules per cell) on the mast cells and basophils surface, and, at lower levels, on 
Langerhans cells, monocytes, platelets and eosinophils surface.  
The classical structure of the FcεRI receptor is tetrameric and consists of an α chain required for 
binding to IgE, a β chain necessary for the maturation of the receptor and for an increase of its 
expression on the cell surface and two γ chains, linked by a disulfide bridge, involved in signal 
transduction (Donnadieu E et al. 2000). The α chain is constituted by an amino-terminal 
extracellular region, a transmembrane region and a cytoplasmic tail. In particular, in the 
extracellular region, there are two glycosylated immunoglobulin domains D1 and D2 which 
constitute the binding site for IgE (Garman SC et al. 2000). The β chain consists of four 
transmembrane domains separated by intra and extracellular loops. The β and γ chains have 
intracellular immunoreceptor tyrosine-based activation motifs (ITAMs) able to mediate the 
association with proximal kinases (Kinet JP 1999). 
In humans, the tetrameric receptor (αβγ2) is constitutively expressed on effector cells of 
anaphylaxis (mast cells, basophils and eosinophils), while the expression of the trimeric form of 
FcεRI (αγ2) is present on antigen presenting cells (APCs) such as monocytes, dendritic cells and 
Langerhans cells (Kinet JP 1999). Despite the lack of the β chain, the function of the receptor on 
APCs is intact, even if the expression density corresponds of about 1/100 compared to that in 
basophils. The expression of FcεRI is influenced not only by the presence of the β subunit but also 
by the local concentration of circulating IgE; in fact, the IgE binding to the receptor constitutes a 
positive signal for the conservation of the receptor on the cell surface (MacGlashan D Jr 2005). 
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Figure 6. Interaction between tetrameric FcRI and IgE or trimeric receptor and IgE. 
 
Differently from humans, the expression of the receptor in mice has been detected exclusively on 
the surface of mast cells and basophils in the classical tetrameric αβγ2 form (Kinet JP 1999). 
However, FcεRI is present on rat eosinophils, monocytes/macrophages, and platelets (Dombrowicz 
D et al. 2000; Gould HJ and Sutton BJ 2008). 
 
FcεRI activation 
The affinity of IgE to FcRI (Ka = 108 - 1011 M1) is 2-5 orders of magnitude higher than that of IgG to 
their receptors. In addition, the high affinity of IgE-FcεRI complex makes that IgE is the only class 
of antibodies that can be strongly retained by the effector cells in the absence of antigen and 
explains the long half-life of IgE in the tissues (about 2 weeks in the skin measured), which it is 
longer than that measured for IgG (2-3 days) (Penichet ML and Jensen-Jarolim E 2010). 
The role played by FcεRI in allergic reactions, both in the "initial phase" which involves mast cell 
activation and degranulation, and in the "late stage", which involves the recruitment and 
activation of inflammatory cells, have been extensively researched.  
In hypersensitivity reaction, allergen induced cross-linking of IgE bound by FcεRI triggering a 
cascade of signaling events, resulting in the release of mediators and gene transcription. Cross-
linking of neighboring FcεRI receptors leads to aggregation and transphosphorylation of cytosolic 
ITAMs on the FcεRI- and -chains by constitutively receptor-associated Lyn tyrosine kinase. The 
initiation of downstream signaling pathways is characterized by an increase in cytosolic calcium, 
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activation of gene transcription of IL-4, TNF, and IL-6, synthesis of cysteinyl leukotrienes and 
prostaglandins and in the fusion of granule with the plasma membrane, followed by the release of 
preformed mediators of hypersensitivity. The release of mediators, during an hypersensitivity 
reaction, may causes vasodilatation, plasma extravasation, tissue edema, mucus production, and 
smooth muscle constriction. 
Subsequently to this initial response, local or recruited IgE-sensitized APC encourage B cells to 
produce IgE, thus maintaining mast cells and APC sensitization and long-term immunologic 
memory and immune surveillance both in situ and systemically. 
 
The low-affinity IgE receptor (CD23) 
The affinity of IgE to CD23 is characterized by a Ka = 107−108M−1 and, unlike FcεRI, the low affinity 
receptor CD23 (FcεRII) does not belong to the immunoglobulin superfamily; it is in fact classified as 
a type 2 of transmembrane protein characterized by a calcium dependent lectin domain, present 
in the distal region of the extracellular domain (C-terminal). CD23 receptor is present in two 
variants, CD23a and CD23b that differ in seven and six amino acids, respectively, at the N-terminal 
cytoplasmic domain level, which contains different signals that can modify their functions (Yokota 
A et al. 1988). CD23a is expressed on antigen-activated B cells prior to differentiation into 
antibody-secreted cells and is involved in IgE antibody-dependent antigen endocytosis, processing, 
and presentation (Gould HJ et al. 2003). The expression of human CD23b isinduced by IL-4 on 
various inflammatory cells as T cells, eosinophils, platelets, monocytes, B cells, DC and epithelial 
cells. 
 
Figure 7. Structure of CD23 
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The CD23 receptor is involved in various processes including the IgE-dependent presentation of 
antigen in human and murine B cells, the inhibition of IgE synthesis in murine B cells through a 
negative feedback mechanism, and the IgE-dependent cancer cells killing by the activation of 
human monocytes (Karagiannis SN et al. 2003). The soluble fragments of the receptor may also, 
depending on their structure, regulate positively or negatively IgE synthesis in human B cells. 
 
Allergy and Tumor 
In the last decades, we have seen a continuous increase in allergies, especially in the industrialized 
world, so much so that it has been proposed a possible involvement of allergy in various diseases 
such as diabetes mellitus, cardiovascular diseases and cancers (Gergen PJ et al. 2000).  
Regarding cancers, it has been proposed that the predisposition to allergic phenomena may play a 
protective role or constitute a risk factor. Since the allergy is an hyper-reactive condition of 
immune system that directs T cells toward a Th2 response, it was assumed that the increased 
immune-surveillance could contrast the proliferation of tumor cells; conversely, the allergic 
condition responsible in some cases of a chronic inflammation resulting in tissue damage and 
repeated shelter, could increase the risk of cancer in certain tissues. For example, the increase of 
lung cancer in asthmatic individuals who have never smoked, supports a direct relationship 
between asthma and lung cancer (Santillan AA et al. 2003). 
The emerging interdisciplinary field of AllergoOncology represents a multifaceted attempt to 
determine the inter-relations of cancer and the Th2 branch of the immune system, which has 
recently greatly expanded from clinical observations to an understanding of the molecular 
mechanism leading to improve targeted therapies. 
Despite numerous studies, it is difficult to draw a precise picture of the association between 
allergies and cancer, often in fact, the results are conflicting with problems associated to the low 
number of subjects with a specific allergy subtype (Turner MC et al. 2006); another complication is 
represented from the patients with neoplasms and immunocompromised, condition that leads to 
an attenuation of the allergic symptoms and the immune system response. Several 
epidemiological studies have investigated a possible association between allergies and other types 
of cancer. In some cases it was demonstrated a protective role of allergies to certain types of 
cancer, for example, a decreased risk associated with a history of hives are seen in males for oral 
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cancer and in females for tumors of digestive system (Vena JE et al. 1985); in many cases, the risk 
of childhood leukaemia tends to be lower in atopic people. In other cases, the allergic 
predisposition was seen instead as a risk factor for glioma (Wang H and Diepgen TL 2005). 
Regarding mechanisms, the overall working hypothesis is that allergens may crosslink IgE 
antibodies fixed to effector cells by means of allergen-associated molecular patterns (AAMPs), 
analogous to tumor antigens by tumor-associated molecular patterns (TAMPs). The immune 
response is, on the one hand, inappropriate hypersensitivity toward innocuous allergens, but on 
the other hand is the activation of anti-cancer inflammation; the final result depends on which 
type of effector cells will be involved (Jensen-Jarolim E and Pawelec G 2012). 
The scenario that is anyway emerging from most epidemiological data indicates that allergic 
predisposition may be associated with a reduced risk for pancreatic cancer, childhood leukemia 
(Turner MC 2012) and for brain tumor (Brenner AV et al. 2002). Conversely, asthma would prove 
to be a risk factor for the onset of lung cancer; this potential positive association could be due to 
many factors such as high levels of free radicals and reduced levels of antioxidants agents in the 
respiratory tract (Boffetta P et al. 2002) and continuous stimulation of cell regeneration for the 
shelter of the inflammatory tissue damage. 
 
IgE in tumor immunotherapy 
Even if the physiological role of IgE has not been completely clarified yet, it was observed that this 
class of immunoglobulins can have a role in cancer prevention. As mentioned above, the 
concentration of IgE is very low in physiological condition but can dramatically increase in 
infections and allergic reactions; epidemiological and experimental studies showed that these 
conditions are negatively correlated to the development of tumors (Turner MC et al. 2006). For 
instance, the development of a syngeneic adenocarcinoma of mice was abolished in 
Nippostrongylus brasiliensis infected mice whether the infection was given before the tumour 
inoculation, and infected mice had less probability to develop spontaneous mammary carcinoma 
(Ogilvie BM et al. 1971). 
These findings have led to the hypothesis of a possible exploitation of the activity and 
characteristics of IgE in tumor immunotherapy. Some studies conducted to investigate a possible 
use of IgE in anti-tumor therapy have come to the conclusion that the redirection of IgE to tumor 
antigens is extremely efficient in triggering an anti-tumor effect (Leoh LS et al. 2015). The ability to 
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activate immune responses that may be directed against tumor is the cause of the success of the 
use of antibodies in cancer therapy. The advancement of technology along with experience in 
clinical applications have enabled researches to design anti cancer antibodies more efficiently and 
it also allowed to study a new class of antibodies as IgE that can be used in addition to that already 
employed in clinical, represented by IgG. IgE have a crucial role in allergic reactions and possess 
several properties that may be advantageous to counteract tumor growth; there are numerous 
studies performed to date that involve IgE in immune therapy against cancer and that 
demonstrate the efficacy of passive and active immunotherapeutic approaches (Leoh LS et. al 
2015).  
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Table 1. Summary of IgE antibodies and mouse models used to evaluate their anti-tumor efficacy (from Leoh LS et al. 2015). 
 
 
Immunotherapy against cancer aims to restore the reactivity of the host's immune system to fight 
cancer and can be divided into two types: passive and active immunotherapy. 
Passive cancer immunotherapy provides a tumor antigen-specific immune response by supplying 
high amounts of effector molecules. Examples of passive immune therapies are those based on 
the use of monoclonal antibodies (mAb) directed against tumor antigens conjugated to toxins, 
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radioisotopes or drugs, and immunocompetent cells such as LAK (Lymphokine Activated Killer) and 
TIL (Tumor Infiltrating Lymphocyte) that is defined adoptive cellular immunotherapy. 
In contrast, active cancer immunotherapy aims at induction of an endogenous, long-lasting tumor 
antigen-specific immune (preventive or therapeutic) response, and consists of the establishment 
and expansion of the endogenous immune cells repertoire (Riemer AB et al. 2007). This approach 
is based on the administration of tumor antigens in an individual in order to activate the immune 
effectors cells; an alternative to induce an immune response in vivo (by administration of a tumor 
antigen as a vaccine to the host’s APCs) is ex vivo stimulation of autologous dendritic cells (DCs) 
with re-application of the DCs to the patient, as a method to break the patient’s immune tolerance 
for tumor-associated antigen. 
 
IgE in passive immunotherapy 
In 1991 Nagy and collaborators, using hybridoma technology, have developed IgE-producing 
hybridomas from splenocytes of Balb/c mice challenged with mouse mammary tumor virus 
(MMTV). Repeated administration of anti-gp36 mAbIgE (i.p. injection of 25 μg of anti-gp36 mAbIgE 
every 4 days, for 8 weeks) in syngeneic mice C3H/HeJ, previously challenged s.c. with 105 or 106 of 
mammary adenocarcinoma MMTV-secreting cells, prevented tumor development in 50% of the 
animals. The antibody had shown no effect on the growth of a MMTV-negative tumor control, 
supporting the idea that a mechanism of cytotoxicity mediated by antigen-specific IgE could play a 
role of anti-tumor immune surveillance (Nagy E et al 1991). 
In 1996, it was produced a second tumor-specific IgE antibody, in this case specific to Ly-2 
expressed on murine T-cell tumors (Kershaw MH et al. 1996). This antibody was a mouse/human 
chimeric IgE and, since human IgE does not bind the murine receptor FcεRI (Kinet JP 1999), in this 
study it was employed a chimeric receptor composed by the human FcεRIα extracellular domain 
linked to transmembrane FcγRIIa and the cytoplasmic tail of the CD3ζ signaling molecule; this 
chimeric receptor was called 3H2. 
In vitro assay showed that mouse CTL effector cells, expressing the chimeric receptor 3H2, were 
able to destroy the mouse E3 thymoma cells that express Ly-2, if these cells were pre-incubated 
with mouse/human anti-Ly-2 IgE. Moreover, if 3H2 effector cells were incubated with E3 thymoma 
cells in presence or absence of mouse/human anti Ly-2 IgE, and then injected s.c. in mice, the 
results showed that the anti-tumor effect was more evident in the presence of mouse/human 
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anti-Ly-2 IgE; in fact, only 1 mouse out of 5 animals developed tumor compared to 4 out of 5 mice 
treated with 3H2 cells alone (Kershaw MH et al. 1996). 
Kershaw and collaborators developed another mouse monoclonal IgE antibody (mIgE 30.6) with 
the purpose to determine a possible antitumor effect of IgE (Kershaw MH et al. 1998). This mouse 
antibody was specific to an antigenic determinant expressed on the surface of human 
adenocarcinoma of the colon-rectal cells, including COLO 205. The study showed that the 
intravenous administration of 1μg of mIgE 30.6 was able to significantly inhibit the growth of COLO 
205 cells, implanted subcutaneously in SCID mice; in this case, the administration was carried out 
5 days after tumor cells implantation. Unfortunately, the effect was not boosted by repeated 
administration of the antibody (Kershaw MH et al. 1998). 
Another study was performed on nude mice challenged i.p. with human HUA ovarian cancer cells, 
expressing FBP (Folate binding protein), and then treated i.p. with human PBMC alone or in 
combination with MOv18-IgE or MOv18-IgG1 (Karagiannis SN et al. 2003). MOv18-IgE is a 
mouse/human chimeric IgE specific to FBP (Gould HJ et al. 1999) similar to MOv18-IgG1 
(mouse/human chimeric IgG1) that containing the same variable regions. This study demonstrated 
that MOv18-IgE significantly increased the survival of mice up to 40 days compared to MOv18-
IgG1 treated mice that showed a survival of 22 days. Since HUA ovarian cancer cells derived from a 
human primary tumor passed in mouse, this xenograft model mimics more closely a possible 
clinical situation. Moreover, with this study it was demonstrated that human monocytes, 
infiltrated into the tumor, exert IgE ADCC (Antibody-Dependent Cell-mediated Cytotoxicity) 
against tumor cells. 
It is through two distinct pathways that monocytes are able to mediate, in vitro, the destroy 
MOv18 IgE-dependent of ovarian cancer cells: by cytotoxicity and by phagocytosis (Karagiannis SN 
et al. 2007). The study of the specific role played by the receptors for IgE has identified in FcεRI the 
mediator of ADCC and in CD23 the mediator of ADCP (Antibody-Dependent Cell-mediated 
Phagocytosis). 
 
Her2/neu (human epidermal growth factor receptor 2) is over expressed in 20-30% of all breast 
and ovarian cancers and is associated with a poor prognosis. The antitumor effect of IgE antibody 
specific for Her2/neu was evaluated; Her2/neu is a member of the EGFR family and mediates cell 
survival and proliferation (Martinelli E et al. 2009).  
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For the treatment of metastatic breast cancer, it was evaluated the efficacy of Trastuzumab 
(Herceptin©), a humanized IgG1 but, even if the effect is evident both employed Trastuzumab 
alone or in combination with chemotherapeutic agents, most of the treated patients showed 
relapse and many patients, instead, do not show any response to therapy based on humanized 
IgG1 (Ahn ER and Vogel CL 2012); this has prompted to seek new strategies to treat tumors over 
expressing HER2/neu.  
In a 2009 study, Karagiannis and colleagues have produced a humanized trastuzumab IgE, 
resulting from the fusion of the original trastuzumab variable regions with the constant region of 
the human IgE; they demonstrated that both antibodies showed, in vitro, cytotoxic effects in cell 
viability test using SK BR-3 human breast cancer cells; moreover, the effects was observable for 2 
days. Trastuzumab IgE mediated ADCC in the presence of U-937 human monocytic cells and, 
degranulation was triggered by trastuzumab IgE using murine colon carcinoma cells expressing 
human Her2/neu (CT26-Her2/neu) incubated with RBL SX-38, a rat basophilic leukemia cells that 
express human FcεRI (Karagiannis P et al. 2009). 
Subsequently, it was developed a fully human anti-Her2/neu IgE antibody that induced, in vitro, 
degranulation of RBL SX-38 in the presence of murine mammary carcinoma cells expressing 
human Her2/neu (D2F2/E2) but was not detected any degranulation in presence of D2F2 cells 
which lack the expression of Her2/neu (Daniels TR et al 2012a). The study suggests that a type I 
hypersensitivity may occur in close proximity of the tumor in which Her2/neu is over expressed on 
the surface of tumor cells and this can facilitates FcεRI cross-linking and  the activation of 
degranulation by effector cells. 
Very interesting is also the development of the mouse/human chimeric IgE specific for human 
MUC1 (Teo PZ et al. 2012) over expressed on tumors arising from glandular epithelium, such as 
breast, ovary, pancreas, and colon cancers. The anti-tumor effect of anti-MUC1 IgE was evaluated 
using 4T1.hMUC1, a murine breast carcinoma cell line expressing the transmembrane form of 
human MUC1; in mice challenged subcutaneously with 105 of 4T1.hMUC1cells and then treated 
with 20μg anti-MUC1 IgE for 5 days, it was observed a 24% reduction in tumor volume. Moreover, 
the treatment with anti-MUC1 IgE showed an increased in the presence of MC in necrotic 
peritumoral regions accompanied by degranulation, compared to mice treated with a control 
antibody. The fact that only in 24% of the mice was observed tumor reduction could be explained 
by the fact that the 4T1 tumors are not vascularized and this could prevent the correct penetration 
of the drug and the effector cells into the tumor mass. 
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Finally, IgE were used against prostate cancer (PCa) (Daniels-Wells TR et al. 2013). Prostate cancer 
is among the most diagnosed cancers the last few years. The prostate specific antigen (PSA) is a 
good target to employed in the immunotherapy against PCa. For this reason it was designed a 
mouse/human chimeric anti-PSA IgE containing the variable regions of the murine monoclonal 
antibody IgG1 AR47.47, specific for PSA. In the study, AR47.47-PSA showed improved antigen 
presentation by human dendritic cells and the activation of both TCD4 and TCD8 lymphocytes 
(Berlyn, K.A et al. 2001). Moreover, anti-PSA IgE-PSA complexes induced an immune activation and 
prolonged the survival of human FcεRIα transgenic mice challenged with PSA-expressing tumors in 
a prophylactic vaccination setting. 
 
IgE in active immunotherapy 
An alternative strategy to the passive immunotherapy based on IgE is to induce anendogenous IgE 
response; the oral immunization of mice with mimotopes of trastzumab (mimic epitopes 
recognized by the anti-Her2/neu trastuzumab), in neutralization and suppression conditions of 
gastric acid, resulted in the formation of specific IgE antibodies for the antigen Her2/neu. It was 
also demonstrated that theseIgE are able to activate, in vitro, effector cells mediating the lysis of 
tumor cells (Riemer AB et al. 2007).  
 
To investigate the IgE-driven immune response in the prevention and control of cancer, our group 
has loaded non-specific monoclonal IgE on the surface of cancer cells through the 3-step 
mechanism (Reali E et al. 2001). The IgE loading mediated by a biotin-avidin bridge was performed 
both in vivo, by systemic administration of reagents such as biotinylated mAb anti-TAA avidin and 
biotinylated IgE mAb in C57BL/6 mice pre-challenged with tumor cells, and in vitro, on the same 
type of tumor cells, prior to inoculation. Exploiting both loading mechanisms, it has been shown 
that the presence of non-specific IgE on tumor cells surface, strongly affects tumorigenicity giving 
rise to a tumor-specific acquired immunity through priming of CD8+ and CD4+ T cells. 
The loading with IgE, unlike that of control IgG, in addition of causing a delay in tumor growth and 
a significant decrease of the speed of tumor development, also confers protective immunity 
against subsequent challenges with untreated tumor cells. This has been seen in two different 
tumor models: the lymphoma cell line RMA characterized by fast growing, known to be 
immunogenic, and a slightly immunogenic colon adenocarcinoma cell line called MC38. 
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For the development of the biotin-avidin bridge, it has been exploited, in the first model the 
presence of the tumor antigen stably transfected Thy 1.1, while in the second model the CEA 
(Carcino embryonic Antigen).  
The presence of IgE triggered an inflammatory reaction at the tumor site level through the 
recruitment and activation of the FcεRI receptor-expressing effector cells such as eosinophils, 
which promoted the destruction of tumor cells, an essential requirement for an efficient priming 
of the specific immune response dependent on CD4+ and CD8+ T cells. The role of eosinophils and 
CD4+ and CD8+ T cells in tumor-specific immune response driven by IgE has been proven through 
experiments of cellular depletion. The depletion of eosinophils,CD4+ and CD8+ T cells in mice prior 
to the injection of tumor cells loaded with IgE demonstrated, in fact, the abolition of the IgE driven 
anti-tumor effect. Finally, preliminary experiments of vaccination, confirmed that this IgE driven 
immunity, mediated by T cells, could actually be used to prevent cancer. The presence of IgE on 
the surface of irradiated tumor cells, in fact, conferred protection in both tumor models at doses 
100 times lower than the corresponding control cells loaded with IgG (Reali E et al. 2001 ). 
 
The adjuvant effect of IgE-coated tumor cells was later confirmed using a slightly different 
strategy; our group studied the effect of mouse IgE in anti-tumor protection by vaccination of mice 
with tumor cells loaded with IgE and infected with Vaccinia Virus. In this study, the introduction of 
Vaccinia Virus and MVA (Modified Vaccinia Virus Ankara) was done for several reasons: 1- to avoid 
the need to kill tumor cells by irradiation (vaccinia virus kill tumor cells in a few days); 2- to use the 
high immunogenicity of vaccinia; and 3- to determine a system suitable to induce cell surface IgE 
expression. Loading tumor cells with IgE was conducted by haptenization followed by loading of 
hapten-specific IgE; this method has allowed to apply the strategy to tumors not characterized by 
specific tumor-associated antigens (TAA) or slightly immunogenic. 
C57BL/6 mice were immunized with loaded with IgE and infected with Vaccinia Virus; as controls 
were used infected RMA cells not loaded with IgE; fifteen days after immunization mice were 
inoculated with live tumor cells. In terms of percentage of survival, 60% of mice immunized in the 
presence of IgE, survived to inoculation of tumor cells not developing tumors even in subsequent 
months; in contrast, 100% of immunized mice in the absence of IgE has developed tumors. 
Moreover, to demonstrate that the anti-tumor adjuvant effect of IgE was due to the interaction 
between IgE and its high affinity FcεRI receptor, we vaccinated wild type mice and αFcεRI knock-
out mice (Dombrowicz D et al. 1993) with TS/A-LACK cells (H-2d mammary adenocarcinoma of 
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BALB/c origin) infected with MVA and loaded with IgE through haptenization. By monitoring the 
tumor growth after inoculation of live TS/A-LACK cells, it was observed that the anti-tumor 
protection observed in wild type mice in the presence of IgE, was completely lost in αFcεRI knock-
out mice. In these mice, indeed, tumor growth was not influenced by the presence or absence of 
IgE and was comparable to that obtained in wild type mice in absence of IgE; this was the first 
demonstration of the crucial role played by the high affinity receptor FcεRI in anti-tumor effect 
driven by IgE (Nigro EA et al. 2009). 
To test the anti-tumor adjuvant effect of human IgE,weemployed a transgenic mouse model 
FcεRIα-/-hFcεRIα+,knock-out for the α chain of the murine FcεRI receptor and knock-in for the 
human α chain (Dombrowicz D et al. 1996). As for experiments with murine IgE, mice were 
vaccinated with the cellular vaccine in the presence or absence of human IgE and they were 
subsequently challenged with live tumor cells and monitored for tumor growth. In the murine 
model with human receptor, two immunizations with cells infected with MVA were able to give 
anti-tumor protection in the presence or absence of human IgE. With a single immunization, 
instead, IgE showed their adjuvant effect by ensuring an anti-tumor protection comparable to that 
obtained with two immunizations. Immunized mice with cells infected with MVA in the absence of 
IgE, in fact, were not protected whenchallengedwith live tumor cells, showing a tumor growth 
comparable to that of non-immunized control mice. 
Finally, in the model with the murine receptor, a single immunization in the presence of human 
IgE, unlike what happened with the mouse IgE, was not able to give anti-tumor protection, since 
tumor growth was comparable to that observed in non-immunized control mice; this was due to 
the fact that the murine receptor was not able to bind human IgE. With this study, our group 
demonstrated the adjuvant effect of human IgE in the anti-tumor vaccination, necessary step for 
the development of a suitable vaccine for a possible clinical application (Nigro EA et al. 2009). 
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Figure 8. Representation of IgE-mediated mechanism in the anti-tumor immunotherapy. 
 
VACCINIA VIRUS 
Vaccinia virus (VV) is a virus belonging to the genus Orthopoxvirus of poxviriade family, and 
presents a linear genome with a double-stranded DNA and performs its replication cycle at the 
cytoplasm level of the host. VV morphologically is not different from other viruses of the same 
genus, such as variola virus, and is characterized by cross-reactivity to antigenic level, in fact, the 
infection by a member of the same family, confers protection against subsequent infections by all 
the others. 
Although it is not known any natural host of VV and its exact origin remains unknown, its 
molecular biology has become the subject of numerous study, since it is a particularly flexible 
instrument for laboratory use, especially as an expression vector (Moss B 1996). The poxvirus 
represents a big target for immune system, although encoding a large repertoire of defense 
molecules versus host, and these molecules are non-essential for virus replication in culture. Some 
of these molecules are secreted by infected cells and prevent the activation of complement or the 
binding of interferons, interleukins or of TNF (Tumor Necrosis Factor). Other regulatory proteins, 
instead, remain within the cells preventing the action of interferon, induction of apoptosis, and 
antigen presentation (Smith GL et al. 1997).  
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MVA, an attenuated and non-replicative vector 
The Vaccinia Virus is an infective virus whose use is subjected to special rules and restrictions, 
including the use of containment equipment with sterile rooms of microbiological safety and 
vaccination of laboratory staff. Two highly attenuated strains of VV, the NYVAC and Modified Virus 
Ankara (MVA), were approved by the intramural biosafety committee Institute of Health American 
(National Institute of Health, NIH) for the use in absence of microbiological safety room and also 
by non-vaccinated staff. The NYVAC virus was realized through selective deletion of eighteen 
genes, some of which are involved in viral tropism or in pathogenicity; in human cell lines, the 
replication of NYVAC virus is blocked at an early stage but a productive infection can be observed 
in African green monkey kidney cells (VERO) and in chicken embryo fibroblasts (CEF) (Tartaglia J et 
al. 1992). 
Differently, MVA virus is blocked at the level of virion assembly, allowing the expression of 
heterologous proteins even in non-permissive cells. MVA virus grows to high titers in CEF cells and 
in a cell line derived from baby hamster kidney (BHK-21), but does not replicate in human cell lines 
and in other mammals due to multiple gene defects (Mayr A et al. 1975). The defects of MVA, 
accumulated after 570 serial passages in CEF, consist of six genomic deletions that determine a 
more highly attenuated phenotype and a considerable host range restriction (Meyer H et al. 
1991).  
 
rMVA, a good tool as vaccine against cancer 
For the experimental therapy against tumors, cancers associated to viruses appear to be good 
targets for vaccines based on MVA; in vitro studies were performed for nasopharyngeal carcinoma 
associated with Epstein-Barr (Taylor GS et al 2004), and in a phase II clinical study it was 
demonstrated the efficiency of a MVA vaccine expressing the E2 antigen of the human papilloma 
virus (HPV) against cervical cancer associated with HPV (Corona Gutierrez CM et al. 2002). 
Vaccines based on recombinant MVA (rMVA) expressing different tumor-associated antigens 
specific for different types of cancer are in preclinical studies in murine models (Mulryan K et al. 
2002; Hodge JW et al. 2003; Espenschied J et al. 2003). A rMVA expressing the MUC1 antigen is 
also in phase I clinical trial in patients with advanced cancer MUC1positive (Rochlitz C et al. 2003). 
Often these vaccines are combined with cytokines such as IL-2 (Rochlitz C et al. 2003) or 
costimulatory molecules which act as adjuvants.  
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Data from a clinical phase I study for the treatment of metastatic melanoma, indicate that 
vaccination with dendritic cells transduced with MVA (in patients who have the HLA-A*0201 allele 
locus in the MHC class I) can activate, in vitro, T cells response against both the recombinant 
antigen of tyrosinase, either against an epitope of the antigen H3 of VV’s envelop (Drexler I et al. 
2003, Di Nicola M et al. 2004). 
 
Based on prior results, our group developed a novel protocol based on membrane IgE for anti-
tumor vaccination to eliminate any possible problem of anaphylactogenicity caused by circulating 
IgE (Nigro EA et al. 2012).  
The construction of a rMVA capable of expressing truncated human membrane IgE (rMVA-tmIgE) 
to be used in anti-tumor vaccination protocols, was generated using an innovative engineering 
method based on an extremely rapid selection procedure and color-driven (red to green gene 
swapping) (Di Lullo G et al. 2009; Di Lullo G et al. 2010).  
rMVA-tmIgE, able to induce the expression of the Cε3Cε4 portion of a human chimeric membrane 
IgE on the surface of cancer cells may be the best solution between efficacy and safety. 
The inability of MVA to replicate in infected cells and therefore infect host surrounding cells, 
ensures that the expression of tmIgE-Cε3Cε4 remains confined to the tumor site. 
 
Figure 9. Genetic scheme of the infection/transfection reagents for the Red-to-Green technology. 
 
 
rMVA-tmIgE was used to infect TS/A-LACK tumor cells in vitro, resulting in transport of tmIgE on 
the surface of infected cells. Human FcεRIα (FcRI-/-hFcRI+) transgenic mice were vaccinated 
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subcutaneously with infected TS/A-LACK tumor cells and after fifteen days they were challenged 
with live TS/A-LACK cells. Mice immunized with rMVA-tmIgE-infected TS/A-LACK cells showed 
significant attenuation of tumor growth compared to mice immunized with control vaccine not 
expressing tmIgE. This second study showed again the role of FcεRI in IgE-active anti-tumor 
immunotherapy (Nigro EA et al. 2012). 
 
Another interesting point in the use of MVA is given by several studies that demonstrated, in 
murine models, the efficacy of intratumoral treatment with MVA, resulting in reduction of the 
tumor mass and in increase insurvival of treated mice (Nemeckova S et al. 2007; Erbs P et al. 
2008). Intratumoral treatment with viral vectors allows the infection of only resident cells inside 
the tumor mass thus ensuring a lower dispersion of viral vector resulting in lower toxicity to 
systemic level and in the increase of the local effect (Luo D and Saltzman WM 2000; Paielli DL et al. 
2000). 
For example, in an experimental study, C57BL/6 were challenged subcutaneously with TC-1/A9 
cells, characterized by the expression of HPV 16 oncogenes and down regulation of H-2b 
molecules. At day 7 and 14 after inoculation of tumor cells, the mice were treated subcutaneously 
with highly immunogenic E7GGG.GUS DNA vaccine expressing the fused gene of modified HPV16 
E7 (E7GGG) with E.coli β-glucuronidase; then, the tumor mass (when became palpable) was 
treated at intratumoral level with two doses (106pfu) of recombinant vaccinia virus MVA 
expressing the gene for murine granulocyte-macrophage colony-stimulating factor (MVA-GM-CSF). 
Data obtained have demonstrated a synergic effect given by the combined treatment of DNA 
vaccine with intratumoral injection of MVA-GM-CSF (Nemeckova S et al. 2007). Indeed, in mice 
also treated with MVA-GM-CSF compared to those treated only with DNA, it was observed a 
significant reduction of the tumor mass volume. Furthermore, it was shown that the local injection 
of MVA-GM-CSF induces the level of CD3+ T cells at the tumor mass level and this indicates that 
intratumoral delivery of MVA-GM-CSF may modify the microenvironment of the tumor, making it 
more accessible to the tumor effector T cells (NemeckovaS et al. 2007). 
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MATERIALS AND METHODS 
Mice 
 
In vivo experiments were conducted on randomized female and male mice (2–4 months of age) 
and performed in accordance with the Italian State and European regulations governing the care 
and treatment of laboratory animals (permission No. 04/2012 and 1193/2015-PR). Transgenic 
mice were bred in a conventional animal facility. 
All mice enrolled in this project were housed with light/dark cycles of 12 hours, temperature of 
22±2 °C, humidity of 55±10%, food and water ad libitum. 
 
BALB/c Wild Type: BALB/c mice (female 2 months of age) were purchased from Harlan 
Laboratories. 
 
IgE-KO: females and males (BALB/c background) kindly provided by Dr. Achatz. This transgenic 
mouse strain, which leads mutation at the level of specific domains in the ε germline gene 
(ΔM1ΔM2), was generated using the technique of gene targeting in embryonic stem cells. These 
mutations result in the absence of the transmembrane and cytoplasmic domains of IgE; moreover, 
their serum IgE levels are reduced of about 94-98% due to a smaller number of IgE-secreting 
plasma cells (Achatz G et al. 1997). 
 
KN1: females and males (BALB/c background) kindly provided by Dr. Achatz. This transgenic 
strainexpresses a chimeric ε-γ1BCR, consisting of the extracellular domain of the  gene and the 
transmembrane and cytoplasmic domains of the 1 gene. In these mice the serum IgE levels are 
increased by 6 times, resulting from an elevated number of IgE-secreting cells (Achatz-
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Straussberger G et al. 2008). The genotype of KN1 will be indicated as "RRHH" since they express 
the IgE-receptor FcRI (R) and produce high levels of IgE (H) after antigen stimulation. 
FcεRI-KO: females and males (BALB/c background) kindly provided by Dr. Dombrowicz. This 
transgenic mouse strain was generated by homologous recombination in embryonic stem cells, 
using a plasmid designed to inactivate the murine α chain of the FcεRI receptor. These mice 
express a murine FcεRI receptor lacking the α chain and consequently unable to bind IgE, 
therefore non-functional (Dombrowicz D et al. 1993). For convenience the genotype of these mice 
will be indicated as “rrhh” since they lostthe α chain of the FcεRI receptor "r" and express normal 
levels of IgE (h). 
 
KN1/FcRI-KO (also called as double mutant, DM): females and males produced by Dr. Vijay 
Yenagi at our animal facility. This transgenic mouse strain was obtained by a cross of KN1 (RRHH) 
males with FcRI-KO (rrhh) females. This murine model is characterized by increased serum 
levels of IgE and by the loss of FcRI(Nigro EA et al. 2016).Therefore the genotype of these mice 
will be indicated as “rrHH”. 
 
Genotyping 
To characterize transgenic mice, DNA was extracted by tail biopsy and tested by PCR (Polymerase 
Chain Reaction). Briefly, tail biopsy of each animal (> 21 days of age) were lysed in 0.5 ml of Lysis 
buffer (1% SDS, 400mM NaCl, 5mM EDTA [pH 8.0], 100mM Tris [pH 8.0]) containing 0.2 mg/ml of 
Proteinase K. Samples were incubated overnight at 56°C and, following phenol/chloroform 
extraction, resulting DNA was precipitated in 100% ethanol, washed with ice-cold 70% ethanol and 
finally resuspended in MilliQ water. DNA purity was assessed by reading the absorbance at 260 nm 
and 280 nm using a Nanodrop spectrophotometer (Thermo Scientific); a ratio of ~ 1.8 is generally 
accepted as “pure” for DNA. Subsequently, 300-400 ng of DNA were amplified using Taq DNA 
Polymerase (Invitrogen). PCR reaction was performed as follows: denaturing at 94 °C for 5 
minutes, amplification for 30 cycles (denaturation for 1minute at 94 °C, annealing for 1 minute at 
60 °Cand extension for 1 minute at 72 °C) followed by 7 minutes at 72 °C. 
To characterize transgenic mice we used different primers. The physiological expression of IgE, 
characterized by the presence of “h” allele, was verified using the following primers: 
h-forward:5’GAAATGGACCTATAAGCTTAGAGCCTTCC3’ 
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h-reverse:5’GATGTTCTTCTAAGCTTTGTCTCAAAG3’ that produced DNA amplicons of 930 bp. 
High levels of serum IgE, characterized by the presence of “H” allele, were verified using the 
following primers: 
H-forward: 5’GAATGGGCTGACCGCTTCCTC3’ 
H-reverse: 5’GGTAAAGGCTGCTTCCTAGTC 3’ that produced amplicons DNA of 1.2 Kb. 
The normal expression of murine FcRI chain, characterized by “R” allele, was tested by:  
R-forward: 5’TTGGCTGCTCCTTCAGACAT3’ 
R-reverse:5’CTCTCTAATGGAGACGGGGC3’ that produced amplicons DNA of 161bp. 
Finally, the loss of the FcRI chain in mice was tested by: 
r-forward:5’CTTGGGTGGAGAGGCTATTC3’ 
r-reverse: 5’CTCTCTAATGGAGACGGGGC3’that produced amplicons DNA of 1.3 Kb.  
The PCR products were analysed by fractionation in a 1.2% agarose gel and visualized with 
ethidium bromide staining. The images were captured using Syngene GBox-HR Gel Doc System. 
 
Cell lines 
TS/A: mammary adenocarcinoma cell line of BALB/c origin, maintained in RPMI-1640(GIBCO), 10% 
FBS, 100 U/ml penicillin, and 100 U/ml streptomycin (Sigma-Aldrich) (Benigni F et al. 2005).  
 
N2C: HER-2/neu expressing N2C primary mammary carcinoma cell line derived from female BALB-
neuT mice. These cells were maintained in DMEM supplemented with 10% of FBS, 100 U/ml 
penicillinand,100 U/ml of streptomycin. 
 
RBL-2H3: rat basophilic leukemia cell line (Kulczycki Jr A and Metzger H 1974) maintained in 
DMEMsupplemented with 10% FBS, 100 U/ml penicillin, and 100 U/ml streptomycin. 
 
CEF: primary culture of chick embryo fibroblasts, kindly provided by Dr. Soprana and Dr.Panigada; 
CEF are maintained in DMEM supplemented with 5% of FBS, 1% of chicken serum (CS) and 1% of 
penicillin/streptomycin.  
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NS1 myeloma cells: murine myeloma cells, kindly provided by Dr. Soprana; these cells were 
maintained in RPMI-FCS (RPMI supplemented with 100 U/ml of Penicillin, 100 µg/ml of 
Streptomicin, 0.25µg/ml of Amphotericin β, 2mM of Glutamine and 10% of FCS). 
 
BHK-21: cell line of hamster kidney (baby hamster kidney) (Macpherson I and Stoker M 1962) 
maintained in RPMI (GIBCO) supplemented with10% bovine serum (FCS) (Euroclone Ltd.) and 1% 
penicillin / streptomycin(GIBCO). 
 
All cell cultures were maintained in a humidified incubator at 37°C with 5% CO2. 
 
Flow cytometry 
-Characterization of N2C cells for Her-2/neu expression: to characterize N2C cells, 5x105 cells were 
washed in PBS and incubated for 1 hour at 4°C with anti c-Erb B2/c-Neu [Ab4], 1:40 in PBS-5% BSA 
(bovine serum albumin); subsequently, cells were washed and incubated for 1 hour at 4°C with 
anti-mouse IgG-biot (Sigma), 1:100 in PBS-5% BSA. Specific binding was revealed by incubation 
with Streptavidin-PE (Pharmingen), 1:300 in PBS-5% BSA for 30 minutes at 4°C, followed by three 
washes.  
 
-Evaluation of CD8+ T cells depletion: CD8+ T cells depletion was assessed by cytofluorimetric 
analysis on peripheral blood. Briefly, 200µl of peripheral blood were collected by venipuncture, at 
tail level, in heparinised tubes; then, the samples were incubated with 2 ml of ACK Lysis buffer 
(150 mMNH4Cl, 10mM KHCO2, 0.1 mMNa2EDTA, in sterile water) for 2 minutes to eliminate red 
blood cells. After washing, cells were incubated with rat anti-mouse CD8a-Cy5 (clone 53-6.7, BD 
Biosciences), 1:100 in PBS-5%BSA for 60 minutes at 4°C, followed by three washes. 
 
-Evaluation of TS/A cells infection: cells, infected with rMVA-tmIgE (Nigro EA et al. 2012), were 
incubated with mouse anti-human IgE-biot (BD Pharmingen), 5 μg/mL in PBS-5% BSA,for 30 
minutes at 4°C. After 2 washes with PBS, specific binding was revealed through Streptavidin-PE 
(Pharmingen), 1:300 in PBS-5% BSA  for 30 minutes at 4°C. 
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All samples were resuspended in 500 µl of PBS and acquired by flow cytometry (FACSCalibur, 
Becton Dickinson, USA) and analysed by CellQuest Pro software. 
 
Implantation of Tumor cells in mice 
-Immunization and implant of TS/A tumor cells: five mice for each group were immunized by 
subcutaneous (s.c.) injection of 105 irradiated (10,000 rad) TS/A tumor cells per animal, at the tail 
base level. 14 days after immunization, mice were s.c. challenged in the abdomen with 2x105of 
live TS/A tumor cells resuspended in 200µl of PBS, using insulin syringe (gauge 29G). 
 
-Implant of N2C tumor cells by subcutaneous administration: five mice for each group were 
challenged with 6x105of N2C cells per animal; tumor cells were resuspended in 200µl of PBS and 
s.c. inoculated in the abdomen, using insulin syringe (gauge 29G). 
 
-Implant of N2C tumor cells by intravenous (i.v.) administration: five mice for each group were  
challenged with 1.2x106of N2C tumor cells per animal; tumor cells were resuspended in 200µl of 
PBS containing 2.5% of heparin and then were inoculated i.v.in the lateral tail vein using insulin 
syringe (gauge 29G). 
 
Tumor growth monitoring 
Tumor growth was monitored every two days by measurement of tumor volume using an 
electronic digital caliper. Tumor volume, V, was calculated using the formula: V = 4/3 x π x (d1/2 x 
d2/2 x r), in which d1 is the horizontal diameter, d2 is the vertical diameter, and r is the thickness of 
tumor protruding from the surface of normal skin. When exceeding 500 mm3 of tumor volume, 
animals were euthanized by cervical dislocation. 
 
Histology 
-Evaluation of tumor growth: to evaluate s.c. N2C tumor growth at different times, labeled 
injection site or tumor mass were harvested at 6, 24 hours and 13 days, then fixed in buffered 4% 
formalin and embedded in paraffin. Multiple 3μm sections from paraffin-embedded samples were 
cut and stained with hematoxylin and eosin for microscopic analysis.  
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-Evaluation of metastases: 35 days post i.v. injection of N2C tumor cells, lungs were analysed for 
metastases using the following procedure: a mid-line incision from below the diaphragm to above 
the throat was used to expose the trachea before opening the chest cavity. Subsequently the 
trachea was cut at the top and the lung was extracted from the thoracic cage. Approximately 2 mL 
of a solution of 15% (v/v) Indian ink in water was infused into the lungs by inserting a cannula into 
the trachea and then placed in sterile water for at least 5 minutes to remove excess ink. 
Thereafter, lungs were placed in Fekete solution (70% [v/v] ethanol, 15% [v/v] sterile water, 10% 
[v/v] formaldehyde and 5% [v/v] of glacial acid) for 48 hours, then tumor masses were visible as 
white nodules on a black normal lung tissue surface (Wexler H 1966). Moreover, samples were 
embedded in paraffin and multiple 3μm sections were cut and stained with hematoxylin and eosin 
for microscopic analysis. 
 
In both cases pictures were taken using the AxioCam HRc with the AxioVisionVs 40 V 4.6.3.0 
(Zeiss).  
 
Mouse serum collection  
Approximately 500µl of peripheral blood were collected by tail vein puncture and incubated for 30 
minutes at room temperature (RT) to allow clotting. Subsequently, serum was obtained after two 
steps of centrifugation at 500g and 2,000g for 10 minutes and stored in a sterile tube at 4°C before 
use. 
 
Mediator release assay 
RBL-2H3 cells expressing the murine FcεRI receptor were seeded and let adhere overnight in96-
well plates in DMEM 10% FBS (8x104 cells / well). The following day, cells were incubated in DMEM 
with 100 ng of mouse IgE k isotype control Ab (clone C38-2; BD Biosciences) for 2 hours at 
37°C.Cells were then washed with PBS and incubated in triggering buffer (119 mMNaCl,5 mMKCl, 
26 mM PIPES, 5.6 mM glucose, 1 mM CaCl2, 0.4 mM MgCl2,0.1% BSA [pH 7.2]) with 100 ngof anti-
mouse IgEmAb (R35-72) for 1 hour at37°C (represented positive control). Alternatively, 2x105of 
N2C tumor cells pre-incubated with serum from mice challenged with tumor cells (or supernatants 
derived hybridomas in case of specific-IgE isolation experiment), were washed, resuspended in 
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triggering buffer, and added to RBL-2H3 cells. Plates were centrifuged for 5 minutes at 300 g and 
incubated for 1 hour at37°C. The release of β-hexosaminidase by RBL-2H3 cells was detected in 
the culture supernatant. In detail, supernatants were transferred to a new plate and 1 mM of p-
nitrophenyl-N-acetyl-β-D-glucosamide (Sigma-Aldrich) in 0.1 M citrate buffer (pH 6.2) was added, 
followed by a 150 minutes of incubation at 37°C.The reaction was stopped using 0.1 M stop 
solution (0.1 MNa2CO3, 0.1 M NaHCO3, [pH 10.0]), and the absorbance was read at 405nm 
(Vangelista L et al. 2005). Results are calculated as percentage of the positive control (IgE plus 
crosslinker). 
 
Isolation of mice tumor specific-IgE 
10 days before the fusion, NS1 myeloma cells (murine myeloma) were thawed and cultured in 
RPMI-FCS (RPMI supplemented with 100 U/ml of penicillin, 100 µg/ml of streptomicin, 0.25µg/ml 
of amphotericin β, 2mM of glutamine and 10% of FCS); the cells were expanded to obtain a 
minimum amount of 50x106. Ten  days before the fusion, the cells were passed 1:2 with fresh 
medium to obtain a population with an exponential growth; in addition, one day before the fusion 
cells were diluted 1: 3 with fresh medium. 
In order to isolate tumor specific-IgE, KN1 mice have been challenged intraperitoneal (i.p.) with 
three doses of 6x105 N2C tumour cells at day -3, -2 and -1 prior to extract spleen and bone marrow 
cells to fuse with NS1 myeloma cells and produce hybridomas. To promote the fusion between 
splenocytes and bone marrow cells with NS1 myeloma cells, the cells were enriched in vitro with 
IL-6 or with splenocytes derived from Balb/c wild type mice. For this reason at day -2, also 
splenocytes from BALB/c were extracted and plated as feeder in 96-well plates (1 spleen/fusion). 
At day 0, KN1 mice were sacrificed and spleen and bone marrow were extracted to isolate cells. 
For spleen, cells were isolated by mechanical disintegration in RPMI P/S/A (RPMI supplemented 
with 100 U/ml of penicillin, 100 µg/ml of streptomicin and, 0.25µg/ml of amphotericin 
β)Collected splenocytes were washed in the same medium and resuspended in 50ml of RPMI 
P/S/A. To isolate the cells from bone marrow, the femurs of KN1 mice were extracted, accessory 
muscles were eliminated and then both extremity of the femurs were cut using a scalpel. 
Following, 2ml of RPMI P/S/A was injected into one of the two extremities of the femur, using a 
1ml insulin syringe with a 29G needle, in order to rinse the inside of the bone marrow and extract 
the contained cells. 
- 42 - 
 
In parallel, myeloma cells were observed using an optical microscope, in order to choose the most 
viable cells and collect them in a 50 ml tube; it was important, in fact, that fusion was performed 
using cells in exponential growth phase and in maximum vitality condition. At this point 
splenocytes, bone marrow cells and NS1 myeloma cells were each in a 50 ml tube; after 
centrifuging at 1300 rpm for 10 minutes at 4 °C and cell counting, splenocytes and bone marrow 
cells have been mixed. Subsequently, NS1 myeloma cells were mixed with splenocytes/bone 
marrow cells in the ratio 1: 4 (1 NS1 myeloma cell : 4 splenocytes/bone marrow cells) in a special 
culture medium RPMI-HAT (RPMI supplemented with 100 U/ml of penicillin, 100 µg/ml of 
streptomicin, 0.25µg/ml of amphotericin β, 2mM of glutamine, 20% of FCS, 1% of HAT 50x 
[hypoxanthine-aminopterin-thymidine; Bio-SPA cod. F0483] and, 4% of Briclone 
[BricloneHybridoma Coning Medium sterile; CABRU cod. 08BRI]). 
The cell suspension obtained was distributed into ten 96-well plates (200μl/well) using a 
multichannel; cells were incubated for 10-15 days at 37 °C and 5% of CO2.At the end of selection in 
RPMI-HAT medium, the supernatants of the wells with cell growth were analyzed for the presence 
of IgE by ELISA test and positive clones for IgE were evaluated for their tumor-specificity through 
mediator release assay. 
 
ELISA test for IgE clones 
In order to evaluated the isolation of IgE clones, a 96-well plate was coated with 2,5 µg/ml of anti-
IgE in PBS (R35-72) overnight and the next day, the plate was blocked with PBS-1% BSA for 2 hours 
at RT. After two washes with PBS-0.05% Tween, supernatants of clones or IgE standard (starting 
from 500ng/ml to 31.3 ng/ml) were incubated in 100µl/well of RPMI-20% FBS at 4°C, overnight. 
Subsequently, after 4 washes with PBS-0.05% Tween, 2µg/ml of anti-IgE biot (R35-118) in PBS-
0.1% BSA was added to plate, for 1.5 hours at RT. Later, the plate was incubated with streptavidin-
HRP (1:1000 in PBS-0.1% BSA), 100µl/well for 1 hour at RT and, after four washes, 100µl/well of 
OPD substrate (OPD, o-phenylenediaminedihydrochloride; Thermo Fisher Scientific) in dark was 
added. The reaction was stopped with 100µl/well of H2SO4 2N and the absorbance was read at 
490nm. 
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In vivo CD8+ T cells depletion 
KN1 mice were depleted of CD8+ T cells by i.v. injections with 300 µg of rat anti-mouse CD8α ascite 
(clone 53-6.7, Abnova) at day 6, 3 and 1 before tumor challenge. Subsequently, CD8+T cells 
depletion was monitored by cytofluorimetric analysis on peripheral blood (as described in the 
previous paragraphs). 
 
Virus Amplification 
For MVA-HcRED or rMVA-tmIgE amplification, an aliquot of each virus was kindly provided by Dr. 
Soprana and Dr. Panigada. MVA-HcRED is a Modified Vaccinia Ankara characterized by the 
presence of the gene for the red fluorescent protein expression HcRED (di Lullo G. et al. 2009). 
rMVA-tmIgE, instead, is a recombinant Modified Vaccinia Ankara characterized by the ability to 
express a truncated version of human mIgE, capable to bind and activate FcRI receptor (Nigro EA 
et al. 2012). 
For the virus amplification we adopted the following protocol: to obtain a high number of virus 
copies (stock), CEF cells seeded on flasks at 80% of confluence, were infected with 50µl of 
concentrated virus. After 4-7 days, virus effective replication was evaluated through CEF lysis and 
then, cells were scraped and transferred into 50 ml falcon/Flask and stored at -80°C. Subsequently, 
samples were thawed and distributed into Nalgene tubes and spun for 1 hour at 24000 g at4°C; 
resulted pellets were resuspended in 1ml of 10mMTris pH 9 per tube, then subjected to three 
cycles of freezing, thawing, vortexed and sonicated and finally spun for 5 minutes at 1800 g at4°C. 
Resulting supernatants were collected and the remained pellets were resuspended in 1ml of 
10mMTris pH 9 and then, the previous steps were repeated. Supernatants obtained were 
collected and pooled together. Pooled supernatant was diluted up to 15 ml with 10mM of Tris pH 
9, added on the top layer of 15 ml 36% sucrose in Tris pH 9; this step was followed by a 
centrifugation for 1 hour at 30000 g at 4°C and in order to obtain: 
 
 
- 44 - 
 
 
After discarding the supernatant, the final pellet containing the virus was resuspended in 1 ml of 
formulation buffer (10mM NaCl + 280mM Tris pH 7.7 [1:1, v:v]) and stored at -80°C before virus 
titration. 
 
Virus titration 
The assessment of viral titer was performed on BHK-21 (baby hamster kidney) cells through the 
method of the terminal dilution. Cells (2000/well) were seeded in 96-well plates and let adhere for 
at least 4 hours. For each titrated stock, serial dilutions in powers of 10 (from 10-2 to 10-12) were 
prepared and seeded in a known volume (50ul) in 16 wells/dilution. 
In the case of viruses expressing HcRED, the detection of positive wells for the infection was 
carried out 3-5 days after seeding by the observation of plate with fluorescence microscopy. In the 
case of viruses lacking the fluorescence cassette, a preliminary screening was carried out to 
identify cytopathic effect 3-5 days after seeding, to allow virus expansion; subsequently, the 
titration plates are replicated on a same number of plates containing fresh BHK-21, and at this 
stage, the more concentrated virus within each well,  results in obvious foci of lysis allowing the 
reliable identification of positive wells. 
Replica plates were then fixed for 10minutes with methanol : acetone (1:1, v:v), washed two times 
with water and incubated 5 minutes with crystal violet 0.5% in water followed byseveral washes to 
remove the excess of colorant. The presence of lysis foci was identified by the absence of purple 
staining, since the suffering infected cells have been detached during fixation with methanol : 
acetone. After counting the positive wells for each dilution, it is possible to calculate the virus titer 
based on the Poisson distribution: m = -ln (f) where m indicates the average number of infectious 
viruses per well, and f is the fraction of non-infected replica. The result is expressed as pfu/ml 
(plaque forming units per ml). 
 
In vitro infection of tumor cells 
To test the good infection of tumor cells by MVA-HcRED virus, TS/A cells were seeded in 6-
wellplate (2x105 cells/well) and infected at 1, 5 or 10 MOI (multiplicity of infection) with virus. 
After 2 hours of infection, cells were washed with medium to remove excess virus and after 
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24hours the infection success was assayed using fluorescence microscopy through the 
identification of cells emitting red fluorescence. 
 
Intratumoral tumor mass treatment  
Mice received a dose of 2x105 tumor cells (TS/A) injected s.c.in the abdomen. When the tumor 
reached 100-200mm3, viruses wereinjected (107pfuof MVA-HcRED or MVA-tmIgE, in 100μl of PBS) 
into tumor mass, using an insulin syringe with a 30 gauge needle.  
After24 and 48 hours from treatment, the infection of cells into tumor mass was evaluated 
through immunohistochemistry assay. 
 
Immunohistochemistry 
Tumor masses deriving from 2 mice per group were collected at 24 and 48 hours after 
intratumoral treatment. Samples were fixed overnight in 10% buffered formalin (Sigma-Aldrich) at 
RT and then moved in 70% ethanol until processing.  
After an abundant washing in water, samples were processed for paraffin embedding through a 
graded ethanol series using STP 120 Spin Tissue Processor (Bio Optica). Paraffin blocks were 
sectioned at 2-3μm for histological and immunohistochemical (IHC) examination, and sections 
were attached to glass slides coatedwith poly-L-lysine. Slides were dried overnight at 37°C to 
optimize sample adhesion. Sections were then deparaffinized with xylene and tissues were 
rehydrated in sequentially graduated ethyl alcohol.  
To test the integrity of samples after processing, all tissues were stained with hematoxylin and 
eosin (H&E) and examined microscopically (images acquired by Olympus BX51, Japan) before IHC 
examination. 
For IHC test, slides were incubated in Sodium Citrate buffer (BioOptica #15-M103) at 90°c for 20 
minutes and after two washes with dH2O, slides were incubated in H2O2 0,3% in TBS (Tris base 50 
mM, NaCl 150 mM in dH2O  at pH 7.5) for 15 minutes to reduce nonspecific background staining 
due to endogenous peroxidase.  
The sections were washed twice in TBS + 0.025% of Triton-X before the application of Blocking 
buffer (5% of total serum, 5% of BSA in TBS) for 1-2 hours at RT. 
To detected tumor cellinfection by MVA-HcRED, 20-50 µl of primary antibody (rabbit anti-vaccinia 
virus, Quartett) in Diluent buffer (1% of BSA in TBS) was applied on the slides; to detected the 
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infection by rMVA-tmIgE, 20-50 µl of goat anti-human IgE-HRP conjugated (KPL) were applied on 
the slides. Samples were then incubated overnight at 4 °C. After being washed three times in TBS + 
0.025% of Triton-X, 20-50 µl of goat anti-rabbit IgG-HRP (Santa Cruz) was applied on each slide and 
samples were incubated for 1 hour at RT.  
Finally, after three washes, tissues were further incubated for 1-5 minutes at RT in a solution of 
DAB chromogen (3,3'-diaminobenzidine), then tissues were counterstained with Mayer’s 
haematoxylin, washed in water, and coverslips were applied with mounting media. To exclude any 
aspecific binding of the secondary antibody, some sections were not incubated with primary 
antibody and were used as negative controls. 
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RESULTS 
Effect of endogenous IgE in tumor growth 
To evaluate a possible role of endogenous IgE in cancer immunosurveillance, we tested the ability 
of TS/A tumor cells to grow in mice engineered to modify their IgE system. For this first 
experiment KN1, IgE-KO and wild type (WT) mice were enrolled; in KN1 mice the serum IgE levels 
are increased by 6 times, resulting from an elevated number of IgE-secreting cells, conversely, IgE-
KO mice are characterized by the absence of circulating IgE.  
For each group were enrolled 5 mice which were immunized (or not) by subcutaneous inoculation, 
at the tail level, of 105 TS/A irradiated cells. After 14 days, the mice were treated subcutaneously 
(in the right flank) with 2x105 of TS/A live cells. Afterwards, when the tumor became palpable, 
about 10 days after inoculation, we started to monitor the growth of the tumor mass and the 
survival of mice enrolled in the experiment (Fig. 1-A and 1-B). 
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Figure 1. IgE-KO, WT and KN1 mice show different susceptibility to TS/A tumor growth. A, Tumor growth curves of 
IgE-KO (black lines), WT (green lines), and KN1 (red lines) mice challenged with live TS/A tumor cells. B, survival of 
IgE-KO, WT and KN1 mice  with (solid lines) or without (dashed lines) prior immunization with irradiated TS/A cells 
as in A. Tumor volume growth curves were estimated by a non-linear mixed effect model and survivals by Kaplan-
Meier analysis (log-rank test). The experiment shown indicates 3-4 replicates. n=5 mice. Error bars indicate SD. *P< 
0.05; **P< 0.01; ***P< 0.001. 
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As shown in Figure 1-A, the immunization with TS/A irradiated cells, prior to inoculation of tumor 
live cells, had no effect on tumor growth in IgE-KO mice. Conversely, in immunized WT mice, the 
tumor volume at 35 days post-TS/A challenge was significantly smaller, as compared to immunized 
WT mice (Fig. 1-A). Moreover, the growth of the tumor mass in unimmunized WT mice was equal 
to that of IgE-KO mice groups (Fig. 1-A). 
In unimmunized KN1 mice, tumor growth was markedly lower than the other groups (IgE-KO and 
WT immunized and not), in fact, after 35 days from tumor implantation, the tumor mass volume 
had not even reached 400mm3, widely exceeded in value in IgE-KO and WT groups. Surprisingly, in 
immunized KN1 group, 100% of animals were completely protected from tumor development (Fig. 
1-A); in addition, immunized KN1mice that were subsequently challenged for a second time, never 
showed tumor growth, demonstrating an anti-tumor immunity persistence (data not shown). 
The trend of tumor growth reflected exactly the trend of survival. Indeed, in IgE-KO mice, the 
survival was not affected by immunization, unlike WT group in which the immunization extended 
the survival of 10 days (Fig. 1-B). Moreover, in accordance with the reduced tumor growth, the 
survival of unimmunized KN1 mice was prolonged compared to the survival of WT and of IgE-KO 
mice, whereas 100% of survival was observed in immunized KN1 mice (Fig 1-B). 
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Characterization of N2C adenocarcinoma cells 
Afterwards, we decided to extend our investigation usingN2C cancer cells, a primary mammary 
carcinoma cell line derived from BALB/NeuT and expressing the HER-2/neu receptor. We 
introduced this cell type in the study because these cells are less aggressive than the TS/A tumor 
cells: in fact no tumor growth is observed in KN1 mice, even without immunization. 
Before their use, N2C cells were characterized for the expression of HER-2/neu through 
cytofluorimetric analysis as shown in figure 2. 
To monitor the effective expression of HER2/neu receptor on cells, 5x105of N2C tumor cells were 
incubated with anti-HER2/neu antibody and the signal of protein expression was detected by use 
of a biotinylated “second” antibody followed by streptavidin. As shown in the histogram of figure 
2, the majority of cells expressed HER2/neu receptor (blue line). As a negative control, N2C cells 
were incubated alone (black line), or incubated with only streptavidin (green line) or with 
biotinylated anti-IgG antibody and streptavidin (red line). 
 
 
 
Figure 2. FACS analysis of HER2/neu expression. N2C tumor cells expressed HER-2/neu (blue line); unstained cells (black line); cells 
either incubated with streptavidin PE (green line) or with biotinylated anti-IgG antibody (red line) are also shown . 
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Tumor protection in KN1 mice without immunization 
In the first in vivo experiment, we had evaluated the protection againsttumor developmentin 
KN1mice after TS/A tumor cells implantation. In this second experiment, we tested whether the 
antitumor protection was also evident using the tumor cell line N2C, characterized by slower 
growth, but high immunogenicity. 
For this experiment were used KN1, IgE-KO and WT (5 mice for each group) mice. 6x105of N2C 
tumor cells were inoculated, subcutaneously, in the right flank of mice and when the tumor 
became palpable, we started to monitor the growth of tumor mass and the survival of mice(Fig. 4 
A and B). 
Generally, tumor growth in IgEKO and WT groups was slower than that observed in the previous 
experiment using TS/A cells; indeed tumor volume never reached the value of 500 mm3 (Fig. 3 A), 
greatly exceeded in the same mice of the first experiment. 
In detail, N2C tumor growth, even without prior immunization, was significantly slower in WT mice 
compared to IgE-KO mice and in KN1 mice no tumor growth was ever observed (Fig. 3 A). Also in 
this case, survival reflected the trend of tumor mass growth. Indeed, as shown in figure 3 B, IgE-KO 
mice died 15 days earlier than WT, while KN1 mice showed 100% of survival (Fig. 3 B). 
At this point we had two independent tumor models in which we observed the existence of an 
antitumor protection given by endogenous IgE. 
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Figure 3. N2C tumor cells do not take root in KN1 mice. A, tumor growth curves in IgE-KO (black line), WT (green 
line), and KN1 (red line) mice challenged with live N2C tumor cells without prior immunization. Beside are shown 
representative images of tumor growth in IgE-KO and KN1 mice. B, survival of the same mice as in A. Tumor volume 
growth curves were estimated by a non-linear mixed effect model and survivals by Kaplan-Meier analysis (log-rank 
test). The experiment shown indicates 3-4 replicates. n=5 mice. Error bars indicate SD. *P< 0.05; **P< 0.01; ***P< 
0.001. 
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To evaluate the engraftment of cancer cells in KN1mice, we performed histological analysis of the 
injected tumor cells area. In this experiment, KN1and WT mice that received 6x105 N2C tumor 
cells, were sacrificed at different time points and the tumor cell implantation area was collected 
and histologically analyzed by hematoxylin-eosin. 
 
 
Figure 4. Kinetic of N2C cells engraftment in KN1 and WT mice. A-F, Hematoxylin & Eosin stained sections of N2C 
tumors at 6, 24 hours and 13 days after injection in KN1 mice (A, C and E) and in WT mice (B, D and F). 
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Histological analysis 6 hours after tumor cells implantation showed that cells engraft equally in 
both KN1 and in WT mice (Fig. 4 A-B); 24 hours later, unlike KN1 mice, in which the tumor has not 
yet grown compared to the previous time (6 hours), in WT mice the growth of tumor cells is 
evident (Fig. 4 C-D). 
After 13 days post tumor cells implantation, when the mass became palpable, only small tumors 
were detected in KN1 mice, while the mass in WT mice were bigger (Fig. 4 E-F). At 30 days post 
inoculation, no tumors in KN1mice had grown, while the tumors in WT mice had grown 
enormously (data not shown). 
 
Protection from lung metastases in KN1 mice 
KN1 and WT mice were also treated with 1.2x106 N2C cells by intravenous injection into the tail 
vein. After 35 days post treatment, mice were sacrificed, their lungs were extracted and stained 
through infusion of Indian Inkdye (infused into the lung via trachea) and finally fixed in Fekete 
solution. Lungs were analysed macroscopically through the observation of tumor foci on the 
external surface; then lungs were embedded in paraffin and multiple 3μm sections were cut and 
stained with haematoxylin and eosin for microscopic analysis. 
As shown in figure 5, in KN1 mice no tumors were identified, unlike WT mice in which the tumor 
masses (represented by white patches) filled almost the whole external surface of the lungs (Fig. 4 
A-B-C-D). Moreover, histological analysis showed that even within the lungs, KN1 mice were tumor 
free, unlike WT mice in which a large number of metastases were observed (Fig. 5 E-F). 
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Figure 5. Metastases do not develop in KN1 mice. After 35 days from i.v. injection of 1.2x10
6
 N2C tumor cells, lungs were analysed 
macroscopically. No tumors were detected in KN1 mice (A, C) in contrast to WT mice in which a large number of metastases is 
observed (represented by white patches) (B, D). Haematoxylin&eosin staining of lungs section are also shown; no tumors are 
detected in KN1 mice even within the lungs (E) compared  to WT mice that showed metastases also inside the tumor mass 
(represented by yellow arrows) (F). 
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The double mutant model  
Since IgE perform their role through interaction with their high affinity receptor FcεRI expressed 
on basophils and mast cells, we wanted to investigate whether the interaction IgE-FcRIwas 
actually responsible for the anti-tumor protection observed in the previous experiments in KN1 
mice. In order to demonstrate the hypothesis that the antitumor effect was drivenby the 
interaction of IgE with the FcRI receptor, we eliminated the high-affinity receptor in the KN1 
murine model. This experiment was initiated by Dr. Vijay Yenagi who performed the crosses to 
obtain double-mutant mice; I was then involved in the genotyping the mice. 
KN1 mice were crossed with FεRIα-KO mice (Figure 6), which express the murine receptor FcεRI 
deprived of the α chain responsible of the interaction of the receptor with IgE and, therefore not 
able to activate the cells on which this receptor is expressed (mast cells and basophils). 
For convenience, the genotype of KN1 mice was indicated as "RRHH", since these mice are 
homozygous for the WT allele of the high affinity receptor (R) and are homozygous for the mutant 
allele for the production of high levels of IgE in the serum (H) (Fig. 6); FεRIα-KO mice were named 
“rrhh”, since these mice do not express the alpha chain of theFcRI receptor (r) and produce 
standard amount of IgE (h) (Fig. 6). As expected, in the first generation F1 we obtained 100% of 
mice with a genotype “RrHh” (Fig. 6); subsequently, we crossed RrHh mice with each other to 
obtain a second generation F2, consisting of the following combination: 1/16 RRHH, 2/16 RrHH, 
2/16 RRHh, 4/16 RrHh, 2/16 rrHh, 1/16 RRhh, 2/16 Rrhh, 1/16 rrhh and finally, 1/16 rrHH (the 
double mutant, DM) as schematically shown in the lower table of figure 6 (Fig.6). 
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Figure 6. Generation of DM (rrHH) mice. Parental KN1 (RRHH) and FcRI-KO (rrhh) mice (P) were crossed to 
generate F1 mice (RrHh). Crossing RrHh mice we obtained all combinations of F2 generation, including the DM mice 
as shown in table below. 
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To select DM mice to be enrolled in subsequent experiments, from each animal of the F2 
generation a tai biopsy was performed to extract DNA and evaluate the genotype by PCR (Fig. 7); 
animals expressing the “H” allele and the “r” allele and not expressing the “h” allele and the “R” 
allele, were selected for subsequent crossing between them (Fig. 7),in order to expand the 
number of this DM group. The new mouse model obtained, has always shown a good vitality, has 
never shown signs of infertility and we never observed symptoms of any disease. 
 
 
 
Figure 7. PCR genotyping of all the expected genotypic combinations in the F2 progeny, including the DM mice. 
Representative gels of PCR product; DM mice (90 and 91) are characterized by the absence of FcRI wild type allele 
(amplicon product size 161bp) and IgE wild type allele (amplicon product size 930 bp) and are characterized by the 
expression of FcRIKO (amplicon product size 750 bp) and expression of allele for the high level of IgE (amplicon 
product size 1200 bp). 
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Loss of antitumor protection in DM mice 
KN1, FεRIα-KO, DM and WTmice were treated subcutaneously with 6x105 N2C tumor cells. In this 
experiment the tumor growth and survival of animals were monitored; furthermore, from each 
animal blood was collected before tumor cells implantation and at day 15, 30 and 45 post tumor 
cells injection, in order to evaluated the presence of tumor specific IgE in the serum. 
As shown in Figure 8, the anti-tumor protection previously observed in KN1 model, was almost 
completely lost in DM murine model, in fact, after 44 days post tumor cells implantation, the 
tumor mass volume in the double mutant mice were significantly greater compared to that in KN1 
mice (Fig. 8-A). Interestingly, tumors in the double mutant mice had grown significantly less than 
the tumors in WT mice (Fig. 8-A); this could be due to the fact that even if DM do not express the 
FcεRIα chain, high level of IgE might be able to engage the low affinity receptor CD23. However 
this possibility was not further investigated. The trend of survival largely reflects what has been 
observed in tumor growth, although the difference in survival between the DM mice and WT mice 
does no reach the level of statistical significance (Fig. 8-B). 
The data provide evidence that the interaction of IgE with FcεRI receptor is essential for the anti-
tumor mechanism implemented by IgE. 
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Figure 8. Tumor protection mediated by IgE requires the FcRI expression.  A, tumor growth curves of WT (green 
line), FcRIKO (grey line), DM (purple line) and KN1 (red line) mice challenged with N2C cells. B, survival of mice in 
A. The experiment shown indicates 3-4 replicates. n=5 mice. Error bars indicate SD. *P< 0.05; **P< 0.01; ***P< 
0.001. 
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The observation of tumor growth in all the mice of the F2 generation showed that animals which 
preserve at least one H allele and one R allele (animals with RRHh, RrHh and RrHH genotype) had 
an intermediate protection against N2C tumor growth (Fig. 9). Indeed, these three groups showed 
a significantly lower tumor growth compared to the block which includes the parental FεRIα-KO 
(and its equivalent rrhh), RRhh (equivalent of WT mice), Rrhh and rrHh groups (Fig. 9). 
 
 
 
 
 
Figure 9. The antitumor protection is proportional to the expression of IgE and its receptor. N2C tumor growth in 
the parental strains (FcRI-KO and KN1) and in all F2 mice genotypes (except DM), grouped in 3 clusters: all mice 
with a hh genotype (FcRI-KO, its F2-equivalent rrhh, the WT-equivalent RRhh, Rrhh), plus rrHh; mice with at least 
one R allele and one H allele (RrHH, RRHh and RrHh); mice with a RRHH genotype (KN1 and its F2-equivalent). 
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Detection of tumor-reactive IgE  
The results obtained so far showed that tumor immunosurveillance was very elevated in KN1 (high 
IgE producer) mice, suggesting a probable production in these mice of tumor-specific IgE in 
response to challenge with tumor cells.  
As previously mentioned, from each KN1, FcεRI-KO,DM and WT mouse of the experiment 
showed in figure 8, blood was collected before N2C implantation and after 15, 30 and 45 days 
from tumor implantation, in order to evaluated, by a -exosaminidase release functional assay, 
the presence of tumor-specific IgE in the serum. The rationale of the assay is that tumor-reactive 
IgE bind to antigens on the surface of N2C tumor cells and then interact with FcεRI receptors 
expressed on the surface of RBL-2H3 cells (Rat Basophilic Leukemia cells), with consequent release 
of mediators of allergic reaction, including β-hexosaminidase. For this reason N2C tumor cells have 
been incubated with sera from WT, FcRIα-KO, KN1 and DM mice and subsequently incubated 
with the RBL-2H3 cells. As shown in figure 10, if N2C tumor cells were incubated with IgE/k isotype 
control antibody there was no significant release of β-hexosaminidase; cross-linked IgE on the 
contrary gave a release of β-hexosaminidase (represented as 100% = positive control of the assay ) 
(Fig. 10). The sera from WT and FεRIα-KO mice did not produce any significant release of β-
hexosaminidase at any time (Fig. 10). On the contrary, at 45 days post N2C challenge, sera from 
KN1 and DM showed a release of β-hexosaminidase significantly higher than the sera of the same 
animals, collected before tumor cells implantation (Fig. 10). A second inoculation of tumor cells 
showed a persistence of tumor specific IgE in the sera of KN1 mice. 
Finally, if IgE in sera of KN1 and DM groups were removed (by depletion), the release of mediator 
of the allergic response was significantly abolished (Fig. 10) demonstrating the specificity of the 
response. 
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Figure 10. Tumor-specific IgE induce the β-hexosaminidase release by RBL-2H3 cells. Sera from FcRIKO, WT, KN1 
and DM mice were collected before and after implantation of N2C tumor cells. Sera of KN1 and DM mice at 45 days 
after challenge, and, for KN1, 30 days after a second tumor challenge induce a significant release by RBL-2H3 cells. 
Depletion of IgE in sera of KN1 and DM groups significantly abolished the release of β-hexosaminidase. Cross-linked 
IgE gave a release of β -hexosaminidase that was represented as 100% (positive control). This figure is a 
representative experiment out of 3 replicas. n = 3 mice. Error bars indicate SD. *P< 0.05; **P< 0.01. 
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Isolation of tumor-specific IgE 
In order to isolate tumor-specific IgE, KN1 mice were challenged i.p. with N2C tumour cells. Spleen 
and bone marrow cells were collected and fused with NS1 murine myeloma cells to produce 
hybridomas. The cell suspension were incubated for 10-15 days and subsequently, the 
supernatants of wells showing hybridoma growth were analyzed for the presence of IgE by ELISA 
test using an anti-IgE antibody. To evaluate the sensibility of the ELISA test we performed a 
decreasing concentration curve of a commercial standard IgE showing that the assay was sensitive 
up to a concentration of 31.3 ng/ml of IgE (data not shown). ELISA test proved that out of 87 
supernatants, selected from the wells that showed cell growth, we could detect only three IgE-
producing hybridomas. These clones were signed as DG5, IG5 and TG3 (Fig.11). 
 
 
 
 
 
 
Figure 11. Identification of tumor specific IgE. Supernatants of hybridomas were analyzed for the presence of IgE 
by ELISA test using an anti-IgE antibody. Out of the 87 tested hybridomas supernatants, only three IgE-producing 
ones were detected . 
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Tumor-specificity assessment of selected clones 
Subsequently, we evaluated the tumor-specificity of the selected IgE-producing hybridomaclones. 
Therefore, N2C tumor cells were incubated with supernatants derived by DG5, IG5 and TG3 clones 
and, subsequently, with RBL-2H3 cells (Fig. 12). In order to be sure of the clonality of the 
hybridomas, before this specificity assay, we performed two subcloning of the selected clones. 
Unfortunately,  none of the selected clones showed specificity towards N2C tumor cells, since the 
release of β-hexosaminidase was never significant (Fig. 12). 
 
 
 
 
Figure 12. Supernatants of IgE-producing hybridomas selected are no able to induce the release of β-
hexosaminidase by RBL-2H3 cells. None of the selected clones (DG515-1, DG515-7, IG58-23, IG58-12, TG324-4, 
TG324-8) induce any significantly release of β-hexosaminidase compare to the negative control (N2C tumor cells 
incubated with standard IgE). 
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CD8+ T cells involvement in IgE-dependent anti-tumor protection 
After showing the role of IgE in tumor immunosurveillance we started looking deeper into the 
mechanism leading to tumor protection. According to our previous studies (Reali E et al. 2001) on 
IgE adjuvanticity in tumor vaccination, the IgE-driven anti-tumor protection is dependent on 
eosinophils, CD4+ and CD8+ T cells. In order to test the involvement of CD8+ T cells in cancer 
immunosurveillance in presence of high levels of IgE, we depleted CD8+T cells in KN1mice, through 
3 consecutive injections (at day 6, 3 and 1 before tumor challenge) of anti-CD8 antibody before 
implantation of N2C tumor cells. Subsequently, the depletion of CD8 + T cells was monitored by 
cytofluorimetry on peripheral blood. 
As shown in Figure 11, on day 0 approximately 90% of CD8+ T cells had been depleted and after 7 
days over 95% of these lymphocytes were eliminated; as control the peripheral blood of KN1 mice 
not depleted of CD8+ was used (Fig. 13-A). Interestingly, depletion of CD8+ T lymphocytes in KN1 
mice dramatically abolished the tumor protection observed in not depleted KN1mice (Fig. 13-
B).This finding demonstrated that the tumor immunosurveillance, observed until now in our 
experiments, depends on CD8+ lymphocytes. 
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Figure 13. Involvement of CD8+ T cells in tumor protection driven by IgE. A, FACS analysis confirm the depletion of 
CD8+ T cells in blood collected from KN1 mice. Compare to undepleted mice, the depletion in KN1 depleted mice 
was >90% at day 0, and > 95% at day 7 post treatment with the anti-mouse CD8 antibody. B, KN1 mice depleted of 
CD8 show a significantly tumor growth compared with undepleted KN1 mice demonstrating the involvement of 
CD8+ T cells in antitumor protection. 
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In vitro test of cancer cells infected with MVA-HcRED 
Since we were unable to isolate an hybridoma producing tumor specific-IgE to be employed in 
therapeutic protocols in mice, we decided to employ the MVA-tmIgE vaccine in therapeutic 
protocols for the intratumoral treatment of solid tumor mass. 
This MVA virus (Modified Vaccinia Virus Ankara) expressing truncated, but functional human 
membrane IgE was previously produced in our laboratory, and has already been used in 
vaccination protocols (Nigro et al 2012). 
Before using the MVA-tmIgE, a control virus MVA-HcRED which express a red fluorescent protein 
was tested in vitro to assess the infection of TS/A tumor cells.For this purpose, 2x105 TS/A cells 
were infected at different MOI with the virus and, the next day, the infection success was 
testedusing fluorescence microscopy for the identification of cells emitting red fluorescence. As 
positive control of infection, CEF cells infected at MOI 1 with MVA-HcRED were used. The infection 
of the TS/A cells was successful, in fact, 24 hours after the infection, TS/A tumor cells expressed 
the red fluorescence given by the expression of the HcRED fluorescent protein (Fig. 14). In 
addition, infection was proportional to the MOI of virus added to cell culture (Fig. 14). 
 
 
 
Figure 14 .MVA-HcRED is able to infect TS/A tumor cells. 2x10
5
 TS/A cells were infected at 1-5 and 10 MOI of MVA-
HcRED. After 24 hours from infection, TS/A tumor cells were able to express the red fluorescence given by the 
expression of the HcRED fluorescent protein. As shown in figure, infection was proportional to the MOI of virus 
added to cell culture (right panel). As positive control of infection, CEF cells infected at MOI 1 with MVA-HcRED, 
were used (left panel).  
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Intratumoral treatment: preliminary data with MVA-HcRED 
In order to understand whether the MVA-HcRED virus was able to infect cells within a tumor mass, 
we performed an in vivo experiment of intratumoral infection. To achieve this aim, mice received a 
dose of 2x105of TS/A tumor cells, injected subcutaneously on the abdominal wall; when the tumor 
mass was palpable (100-200mm3 of volume), it was treated with107 pfu of MVA-HcRED by 
intratumoral injection and after 24 and 48 hours from treatment, the infection of cells into the 
tumor mass was tested through immunohistochemistry assay. 
IHC assay showed that MVA-HcRED was able to infected the cells into the tumor mass (Fig. 15); 
the signal of infection (represented by brown staining) was evident at 24 and 48 hours after 
intratumoral treatment (Fig. 15); as negative control of the experiment we used a tumor mass 
treated with PBS and, as expected, in this case we had not obtained any signal of infection as 
shown in figure 15. 
 
 
 
 
Figure 15. MVA-HcRED is able to infect cells within the tumor mass. IHC assay, for the presence of vaccinia virus 
show that MVA-HcRED infect the cells within the tumor mass after 24 and 48 hours from intratumoral injection of 
MVA-HcRED. The signal of infection are represented by brown staining (indicated with yellow arrows); as negative 
control of the experiment was used a tumor mass treated with PBS (NT). 
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In vitro test of cancer cells infected with MVA-tmIgE 
Before assessing the ability of the rMVA-tmIgE to infect cells within a TS/A tumor mass, we 
evaluated the infection of TS/A tumor cells in vitro. To this end 2x105 TS/A cells, infected with 
rMVA-tmIgE at 1, 5 and 10 MOI, was assayed for the expression of human mIgE on cell surface, 
through cytofluorimetry using an anti-human IgE antibody as tracer.  
After 24 hours from infection, cytofluorimetry demonstrated that rMVA-tmIgE virus was able to 
infect tumor cells and express the human membrane IgE on the cell surface (Fig. 16). Furthermore, 
the infection was proportional to virus MOI used to infect TS/A tumor cells in vitro (Fig. 16). 
 
 
 
 
Figure 16. FACS analysis for the expression of human IgE in TS/A tumor cells infected with rMVA-tmIgE virus at 1, 
5 and 10 MOI. 24 hours after infection, tumor cells express human membrane IgE on their surface (pink line). The 
expression is proportional to MOI of virus used as shown in figure. Negative controls are both uninfected TS/A 
(black line) and infected TS/A incubated with only secondary antibody (green line). 
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Intratumoral treatment with rMVA-tmIgE 
Next we tested the rMVA-tmIgE ability to infect cells within the tumor mass. This experiment was 
performed to evaluate the capacity of rMVA-tmIgE to express in vivo the human membrane IgE on 
the surface of tumor cells after intratumoral injection of the virus. Mice received a dose of 2x105 
TS/A tumor cells, injected subcutaneously on the abdomen and then the tumor mass was treated 
with 107pfu of rMVA-tmIgE by intratumoral injection. Subsequently, after 24 and 48 hours from 
treatment with the virus, the tumor mass was harvested and the infection of cells into the mass 
with the expression of human IgE on the cells surface was tested through immunohistochemistry 
assay using an anti-vaccinia virus and an anti-human IgE antibodies, respectively. 
IHC assay showed that rMVA-tmIgE was able to infected the cells into the tumor mass already 
after one day from infection (Fig. 17-A); the signal of infection (represented by brown staining) 
was evident at 24 and 48 hours after intratumoral treatment (Fig. 17-A). Considering the ability of 
rMVA-tmIgE to express the human IgE in vivo, the signal of human IgE expression is evident at 24 
and 48 hours after intratumoral treatment(Fig. 17-B), even if the signal of expression is much 
lower compared to the signal of infection (Fig. 17-A,B). As negative control of the experiment, a 
tumor mass treated with PBS was used and, as expected, also in this case we did not obtain any 
signal of infection or human IgE expression. 
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Figure 17. In N2C tumor mass, cells infected with MVA-tmIgE express the human IgE on their surface.A, IHC assay, 
for the presence of vaccinia virus show that MVA-tmIgE is able to infect, in vivo, cells within the tumor mass after 24 
and 48 hours from intratumoral treatment. B, MVA-tmIgE express the human IgE on infected cells surface. The 
expression was detectable already after 24 and 48 hours post intratumoral treatment. The signal of infection or 
human IgE expression is represented by brown staining (indicated with yellow arrows); negative control is 
represented by tumor mass treated with PBS (NT). 
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DISCUSSION 
The potential of IgE to induce an anti-tumor protection is the basis of the innovative research field 
called Allergo-Oncology (Jensen-Jarolim E et al. 2008; Singer J and Jensen-Jarolim J 2014).  
Various studies have demonstrated the capacity of IgE to  induce of tumor cells and to prevent 
tumor growth (Karagiannis SN et al. 2008; Karagiannis P. et al. 2009; Daniels TR et al. 2012; Nigro 
EA et al. 2013; Josephs DH et al. 2014). All studies related to this research area were inspired by 
epidemiological data that suggest allergies as a factor that can reduce the incidence of certain 
types of cancer, such as pancreatic tumor and glioma (Turner MC et al. 2006; Leoh LS et al. 
2015).According to these epidemiological data, the allergic condition would favor the prevention 
of tumor development; however, this is highly dependent on the type of tumor considered, and on 
the type of allergic disorder. 
These studies clearly indicate that are-direction of IgE on tumor cells surface, is able to determine 
cellular cytotoxicity. The re-direction of IgEwas made through the development of monoclonal IgE 
specific to tumor antigens such as, to the mouse mammary tumor virus (MMTV) (Nagy E et al. 
1991) or to the antigen specific to an antigenic determinant expressed on the surface of human 
adenocarcinoma of colon-rectal cells as COLO 205 (Kershaw MH et al. 1998). 
In addition, the construction of a chimeric human-mouse monoclonal IgE called MOv18, specific 
for the FBP(Folate-binding protein) expressed on ovarian carcinoma cells (Gould HJ et al. 1999), 
allowed to demonstrate the involvement of human monocytes as anti-tumor effectors cells in a 
tumor xenograft model performed in scid mice (Karagiannis SN et al. 2003). 
In an initial work of our group the ability of mouse IgE, loaded on the surface of tumor cells, to 
influence the tumor growth and to give protection in terms of anti-tumor vaccination it has been 
demonstrated in C57BL/6 mice using two type of tumor cells: a cell line of adenocarcinoma and a T 
lymphoma cell line (Reali E et al. 2001). In this study, the loading of IgE was obtained through the 
3-step strategy, based on the biotin-avidin bridge, performed both in vitro prior inoculation in 
mice orin vivo. The use of the 3-step strategy eliminated the need to build specific IgE against 
tumor antigens. The vaccination protocol consisted in inoculation of two doses of irradiated tumor 
cells, loaded with IgE or IgG, followed by administration of live tumor cells at 15 days after the last 
immunization. Vaccinated mice showed a strong protection against tumor growth in the group 
vaccinated by IgE-loaded tumor cells, indicating the formation of an adjuvant effect driven byIgE. 
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Since the inoculation of live tumor cells occurred in the absence of IgE, the protective effect driven 
by IgE was to be attributed to the stimulation of the immune system by prior vaccination with 
tumor cells loaded with IgE. Moreover, the presence of eosinophils, CD4+ and CD8+ T cells had 
been shown to be crucial for the establishment of anti-tumor immunity; in fact, their depletion 
brought to the abolition of anti-tumor protection even in mice immunized with IgE-loaded cells 
(Reali E et al. 2001). 
Subsequently it was demonstrated, in animal models, the involvement of IgE in anti-tumor 
immune response through a process that involves the interaction of IgEwith the high affinity 
receptor FcεRI. In this study (Nigro EA et al. 2009), it was observed that the IgE driven anti-tumor 
protection observed in wild type mice was completely lost in mice knock-out for FcRI receptor. 
This result indicated the crucial role played by the high affinity FcRI receptor in the anti-tumor 
effect driven by IgE. 
The activation of FcεRI receptor, expressed on murine mast cells and basophils, leads to a potent 
degranulation of these cells and results in the release of chemotactic mediators such as histamine, 
proteoglycans, β-hexosaminidase, thromboxane and leukotrienes; mediator release induces the 
recruitment of effector cells, responsible for the development of a powerful inflammatory process 
(Mukai K et al. 2005).In terms of anti-tumor applications, the development of local inflammation 
would result in tumor cell death and processing of tumor antigens, thus causing the onset of a 
strong immune response against tumor. Furthermore, the use of a transgenic mouse model, 
knock-out for the α chain of the murine FcεRI receptor and knock-in for the human α 
chainFcRIhFcεRIα+ receptor (Dombrowicz D et al. 1996), allowed to continue the studies using 
human IgE, a fundamental step for a possible clinical application of IgE-driven anti-tumor 
vaccination. Human IgE showed an adjuvant effect in anti-tumor vaccination in “humanized mice”, 
but not in wt mice, highlighting the species-specificity of IgE-receptor interaction (Nigro EA et al. 
2009). 
Based on these results, in this thesis project we wanted to investigate whether endogenous IgE 
also had an anti-tumor adjuvant effect, given that previous studies were related onexogenous IgE 
only. 
For this purpose, we employed IgE-KO mice that are characterized by the absence of the 
transmembrane and cytoplasmic domains of IgE and in which serum IgE levels are reduced of 
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about 94-98% due to a smaller number of IgE-secreting plasma cells (Achatz G et al. 1997).The s.c. 
inoculation of TS/A tumor cells in IgE-KO and WT mice showed a very similar growth. 
In parallel, we decided to immunize some IgE-KO and WT mice with irradiated TS/A tumor cells 
prior to challenge mice with live tumor cells. In this case the tumor growth in WT mice was 
significantly decreased and the survival was prolonged respect to not immunized WT mice. 
Differently, tumor growth and survival in immunized IgE-KO mice was absolutely not changed 
compared to non-immunized mice. This result indicates that the protection observed in 
immunized WT mice depends on the anti-tumor IgE response induced by immunization. 
After documenting the effect of the loss of IgE expression, we investigated how the system would 
act, instead, in the case of an increase of IgE concentration. We used a transgenic mouse model 
called KN1; this transgenic strain expresses a chimeric ε-γ1 BCR, consisting of the extracellular 
domain of the  gene and the transmembrane and cytoplasmic domains of the 1 gene. The 
resulting antibody is a true IgE but is characterized by a 1 transmembrane domain anchored on 
the B cell which, unlike the transmembrane domain causes an alteration in homing and an 
increase in survival of plasma cells. The KN1 mice model was very suitable for this part of the 
project since, in these mice, the number of IgE-secreting B cells increases up to 10 times in the 
bone marrow and the levels of IgE in the serum increase by 4-6 times compared to WT mice, after 
interaction with the antigen (Achatz-Straussberger G et al. 2008). 
KN1 mice, immunized with irradiated TSA cells and then challenged with live tumor cells, displayed 
no tumor growth and presented 100% of survival; moreover, if tumor cells were inoculated 
without prior immunization, tumor growth in KN1 mice was still much lower than the growth 
observed in WT andIgE-KO mice. To confirm this data, in addition to TSA tumor cells, we 
introduced another type of tumor cells in our experiments: the N2C tumor cells, a primary 
mammary carcinoma cell line derived from BALB-Neu T mice (Melani C. et al. 2003), which are less 
aggressive than TSA tumor cells. Using N2C tumor cells, a complete protection against tumor 
growth in KN1mice was observed even without prior immunization, and the survival rate was 
100% (at difference from WT and IgE-KO mice). Furthermore, on some KN1 mice we performed a 
second challenge with tumor cells, but we never observed any tumor growth in any KN1 mice 
(data not shown). 
IgE exerts its role through the interaction with its two receptors, the high affinity FcRI receptor 
(Kinet JP 1999)which in mice is expressed on mast cells and basophils, and the low affinity CD23 
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receptor expressed on B cells and on antigen presenting cells (Kijimoto-Ochiai S 2002). A previous 
study had already shown that the effect of IgE in anti-tumor vaccination depends on the high 
affinity receptor and not on the low affinity receptor (Nigro EA et al. 2009). 
To demonstrate that the protection observed in KN1 mice was due to the interaction of IgE with 
FcRI, we planned to remove the high affinity receptor in these mice. To this purpose, we crossed 
KN1 mice with FcRI-KO mice, in order to obtain a double mutant mice (DM) characterized by 
high levels of IgE, but lacking the high-affinity receptor. 
The challenge with N2C tumor cells in DM mice showed that the antitumor protection previously 
observed in KN1mice, was largely lost, clearly demonstrating that the IgE-FcRI interaction is 
fundamental for IgE-driven anti-tumor immune surveillance. It should be emphasized that the 
tumor growth in DM mice was anyway significantly lower than in WT mice, and this may be due to 
the fact that IgE present at high levels in DM, could have activated alternative protective 
mechanisms. The activation of alternative mechanisms may also explain the fact that tumor 
growth in IgE-KO and FceRI-KO mice is not the same as it would be expected if the IgE-FcRI axis 
were the only involved in the IgE-driven antitumor effect driven by IgE. Therefore, a concomitant 
minor role played by CD23 might not be excluded. However, no experimental results are available, 
since they would require the lenghty and cumbersome construction of double mutants. 
The fact that the immune-surveillance in IgE-KO mice is strongly decreased and in KN1 mice is 
greatly increased suggests that in these mice the activation of an antitumor response driven by 
IgEis a consequence of the tumor cells challenge.  
Therefore we tried to detect tumor-specific IgE in sera of both KN1 mice and DM mice challenged 
with N2C tumor cells. Since conventional immunoassays turned out to be not sensitive enough for 
this purpose, we employed a very sensitive functional assay previously developed in our 
laboratory (Vangelista L et al. 2005). Indeed, sera derived from KN1 and DM mice were able to 
induce a significantly release, in vitro, of mediators such as -hexosaminidase, after incubation 
with tumor cells, unlike sera derived from WT and FcRI-KOmice that did not induce any release 
of mediators. Furthermore, the depletion of IgE from KN1 and DM sera, in vitro, completely 
abolished the release, validating the contribution of IgE. 
This result encouraged us to try to isolate tumor-specific IgE through hybridoma technology, 
starting from spleen or bone marrow of KN1 mice in vivo challenged with the tumor. IgE 
hybridomas are extremely rare and actually only one of them is commercially available (Eshhar Z 
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et al. 1980). It was then surprising to obtain 3 IgE hybridomas out of a total of 87 hybridomas. 
Unfortunately, none of them showed any specificity for the tumor cells. Considering that the 
frequency of antigen specific hybridomas recovered in any experiment is rather low (however less 
than 5 %), our results just stress that very large screens, unfeasible in our laboratory limitations 
would be necessary. 
A fundamental issue for this study was to understand how IgE operate to give the observed 
antitumor effect. In previous studies, it was demonstrated that the adjuvant effect of exogenous 
IgE in tumor treatment depended on CD8 + T cells (Reali E et al. 2001; Platzer B et al. 2015). 
Therefore, we have depleted the CD8+ T cells in KN1mice prior to the inoculation of N2C tumor 
cells; this allowed the growth of the tumor in KN1 mice, demonstrating that the anti-tumor 
immune surveillance driven by IgE is largely mediated by an immune response dependent of CD8+ 
T cells. 
The mechanism that involves IgE and CD8+ T cells in anti-tumor protection remains to be 
discovered. In a recent study it was shown that IgE-driven antigen cross-presentation by mouse 
dendritic cells, modified to express human FcRI, activated the production of anti-tumor cytotoxic 
CD8+ T lymphocytes (Platzer B et al. 2015). 
Since the high affinity FcRI receptor is not present on murine dendritic cells, other cells 
expressing FcRI must be involved in such mechanisms. Murine mast cells could induce the 
activation of T cells by releasing exosomal materials, including IgE-antigen complexes (Raposo G et 
al. 1997; Skokos D et al. 2003). 
Many studies (Leoh LS et al. 2015) have tried to prove that the anti tumor immunosurveillance 
mediated by IgE could be even more effective in humans, since human dendritic cells express the 
high affinity receptor and may directly participate in the response. The anti-tumor response driven 
by IgE could be the result of an evolutionary compromise, developed to transmit the anti-parasitic 
and anti-tumor surveillance activities. 
Slight deviations from the "optimal IgE response" may explain the high incidence of atopy, which, 
in some cases results in a reduced risk of developing cancer (Penichet ML and Jensen-Jarolim E 
2010; Josephs DH et al. 2013; Josephs DH et al. 2014). 
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In the second part of this study, we tried to develop another tool for the treatment of solid 
tumors. This tool was represented by rMVA-tmIgE (Modified Vaccinia Virus Ankara expressing a 
truncated form, but functional, of human membrane IgE) previously developed at our laboratories 
(Nigro EA et al. 2012). 
The most important limitation for a possible clinical application of this anti-tumor treatment 
strategy is the danger of the soluble IgE administration to patients. Even a small fraction ofIgE 
aggregated in circulation has, in fact, the potential to determine a potent and in some cases fatal 
anaphylactic reaction. An unexpected recognition of antigens by soluble circulating IgE or IgE 
already bound to FcRI receptor can, in fact, lead to the formation of immune complexes capable 
to activate the receptors present on the surface of mast cells and basophils, resulting in a powerful 
cell degranulation which leads to systemic anaphylaxis. 
To avoid the potential problems of soluble IgE, the use of IgE in their membrane isoform allows to 
maintain the reactivity at a local level, avoiding any possible systemic complication. 
The possibility of employing the membrane IgE (mIgE) relies on previous studies performed in our 
laboratory on the interaction between human mIgE and FcRI receptor (Vangelista L et al. 2005). 
The study was inspired by structural evidence about the architecture of binding sites of IgE and 
FcRI (Vangelista L et al. 2003), by the ability of mIgE to bind the soluble forms of receptor 
(Yanagihara Y et al. 1994; Vangelista L et al. 2002) and by structural assembly knowledge of mIgE 
(Bestagno M et al. 2001). It was demonstrated that mIgE are able to bind and activate the FcRI 
receptor, independently from the presence of antigen; in the case of human IgE (at difference with 
murine IgE) this is true also for a truncated portion of mIgE, comprising only C3 and C4domains 
(Vangelista et al. 2005). 
The employment of rMVA-tmIgE, expressing the Cε3Cε4 portion of a chimeric human membrane 
IgE on the surface of tumor cells, represents, to our knowledge, the best solution for both efficacy 
and safety. The rMVA-tmIgE was generated using an innovative engineering approach based on an 
extremely fast selection, obtained by fluorescence-activated cell sorting approach (red to green 
gene swapping) (Di Lullo G et al. 2009; Di Lullo G et al. 2010). That rMVA-tmIgE allows to obtain 
tumor cells infected with MVA and expressing the Cε3Cε4 fragment on cell surface. The 
impossibility of MVA to replicate in infected cells and then infect host cells surrounding, ensures 
that the expression of tmIgE-Cε3Cε4 remains confined to the tumor site. 
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For this reasons, a novel protocol based on rMVA-tmIgE for anti-tumor vaccination was developed 
(Nigro EA et al. 2012). rMVA-tmIgE was used to infect TS/A-LACK tumor cells in vitro. Then infected 
TS/A-LACK tumor cells were used to vaccinate human FcεRIα mice (FcRI-/-hFcRI+). After fifteen 
days, vaccinated mice were challenged with live TS/A-LACK cells. This study showed that mice 
immunized with rMVA-tmIgE-infected TS/A-LACK cells showed a significant attenuation of tumor 
growth compared to mice immunized with control vaccine not expressing tmIgE (Nigro EA et al. 
2012). 
On the basis of these data, we conceived that the same IgE-driven effect obtained treating the 
tumor cells in vitro could be obtainable treating the tumors in vivo with the same recombinant 
virus. We therefore planned to perform in situ infection with rMVA-tmIgE which would make the 
tumor cells express the tmIgE on the surface, transforming the tumor cells in in vivo vaccines. 
Several studies have demonstrated, in murine models, the efficacy of intratumoral treatment of 
solid tumors with Vaccinia viral vectors and MVA with a consequent reduction of the tumor mass 
volume and an increase of survival (Luo D and Saltzman WM. 2000; Paielli DL et al. 2000; 
Nemeckova S et al. 2007). Intratumoral treatment with viral vectors allows the infection of only 
residents cells within tumor thus ensuring less dispersion of viral vectors resulting in lower 
systemic toxicity and in an increase of the effect on tumor site (Paielli DL et al. 2000). 
For this reason, in the last part of my project, we have begun to evaluatethe capacity of rMVA-
tmIgE to express, in vivo, the human membrane IgE on tumor cells surface after intratumoral 
injection of vaccine in WT mice. The expression of IgE on the membrane of resident cells within 
the tumor mass is crucial, as, it is the key to trigger an allergic reaction against the tumor. 
The tumor mass was treated with 107plaque forming unit (pfu) of rMVA-tmIgE by an intratumoral 
injection. After 24 and 48 hours from the treatment, the tumor mass was extracted and both the 
infection of cells into the tumor mass and the expression of human IgE on the cells surface were 
tested through immunohistochemistry (IHC). IHC assay showed that rMVA-tmIgE was able to 
infected the cells into the tumor mass already one day after the intratumoral treatment. 
Regarding the ability of rMVA-tmIgE to express the human IgE in vivo, the signal of the human 
truncated mIgE expression was evident already one day after the intratumoral treatment, even if 
the signal of tmIgE expression was much lower compared to the signal of MVA infection. 
In our future experiments, we plan to treat solid tumors induced after subcutaneous inoculation of 
TSA or N2C tumor cells in the "humanized" mouse model FcεRIα-/-/hFcεRIα+, with intratumoral 
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injections of the viral vector rMVA-tmIgE. Then we will assess the response of treatment in terms 
of reduced tumor growth and increased survival. We expect to obtain an inflammatory reaction 
against the tumor (similar to that triggered during an allergic reaction) caused by the binding of IgE 
expressed on the surface of cells, present in the tumor mass, with FcεRI receptor expressed on the 
membrane of mast cells and basophils. Such IgE-dependent response would lead to a subsequent 
long-term protection (IgE-independent) based on a cell-mediated CD8-dependent response.  
rMVA-tmIgE could be the starting point for the construction of multiple rMVA vectors expressing, 
in combination with human IgE, adjuvant molecules such as interleukins IL-10 and IL-15 that have 
already been studied in the antitumor field for their ability to increase the innate immune 
response (Steel JC et al. 2012) and chemokines such as CCL5 (RANTES), able to recall T cells, 
eosinophils, and basophils within the tumor site (Aldinucci D and Colombatti A 2014).The 
technology for the production of multiple rMVA was developed by our group and is already in use. 
We think that the results that could be obtained with this study will be a step forward towards 
translational studies about anti-tumor vaccination and anti-tumor immunotherapy in human. 
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